

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number  
**WO 2004/002490 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/535**,  
31/54, 31/03, C07D 498/04, 491/04, 513/04, 519/00

(21) International Application Number:  
PCT/EP2003/006754

(22) International Filing Date: 25 June 2003 (25.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/391,710 26 June 2002 (26.06.2002) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AXTEN, Jeffrey, Michael** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **DAINES, Robert, A.** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **DAVIES, David, Thomas** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **GALLAGHER, Timothy, Francis** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **JONES, Graham, Elgin** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **MILLER, William, Henry** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089,

Collegeville, PA 19426-0989 (US). **PEARSON, Neil, David** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **PENDRAK, Israil** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US).

(74) Agent: **VALENTINE, Jill, Barbara**; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/002490 A2

(54) Title: COMPOUNDS


(57) Abstract: Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.

## Compounds

This invention relates to novel compounds, compositions containing them and their use as antibacterials.

- 5 WO99/37635, WO00/21948, WO00/21952, WO00/43383, WO00/78748, WO01/07432, WO01/07433, WO02/08224, WO02/24684, WO02/50040, WO02/56882, WO02/96907, PCT/EP02/05708, WO03010138, WO01/25227, WO0240474 and WO0207572 disclose cyclohexane, piperidine and piperazine derivatives having antibacterial activity.

- 10 This invention provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof:




(I)

wherein:

15

$R^A$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system of structure:



containing 0-3 heteroatoms in each ring in which:

- 20 at least one of rings (x) and (y) is aromatic;  
 one of  $Z^4$  and  $Z^5$  is C or N and the other is C;  
 $Z^3$  is N,  $NR^{13}$ , O,  $S(O)_x$ , CO,  $CR^1$  or  $CR^1R^{1a}$ ;  
 $Z^1$  and  $Z^2$  are independently a 2 or 3 atom linker group each atom of which is independently selected from N,  $NR^{13}$ , O,  $S(O)_x$ , CO,  $CR^1$  and  $CR^1R^{1a}$ ;  
 25 such that each ring is independently substituted with 0-3 groups  $R^1$  and/or  $R^{1a}$ ;  
 one of  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$  is N, one is  $CR^{1a}$  and the remainder are CH, or one of  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$  is  $CR^{1a}$  and the remainder are CH;  
 30  $R^1$  and  $R^{1a}$  are independently hydrogen; hydroxy;  $(C_{1-6})$ alkoxy optionally substituted by  $(C_{1-6})$ alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups,  $CONH_2$ ,

- hydroxy, (C<sub>1-6</sub>)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C<sub>1-6</sub>)alkylsulphonyloxy; (C<sub>1-6</sub>)alkoxy-substituted(C<sub>1-6</sub>)alkyl; hydroxy (C<sub>1-6</sub>)alkyl; halogen; (C<sub>1-6</sub>)alkyl; (C<sub>1-6</sub>)alkylthio; trifluoromethyl; trifluoromethoxy; cyano; carboxy; nitro; azido; acyl; acyloxy; acylthio; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>1-6</sub>)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C<sub>1-6</sub>)alkyl, acyl or (C<sub>1-6</sub>)alkylsulphonyl groups, or when Z<sup>3</sup> and the adjacent atom are CR<sup>1</sup> and CR<sup>1a</sup>, R<sup>1</sup> and R<sup>1a</sup> may together represent (C<sub>1-2</sub>)alkylenedioxy; provided that R<sup>1</sup> and R<sup>1a</sup>, on the same carbon atom are not both optionally substituted hydroxy or amino;

provided that

- (i) when R<sup>A</sup> is optionally substituted quinolin-4-yl:  
 it is unsubstituted in the 6-position; or  
 it is substituted by at least one hydroxy (C<sub>1-6</sub>)alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position; or  
 it is substituted by at least one trifluoromethoxy group; or  
 R<sup>1</sup> and R<sup>1a</sup> together represent (C<sub>1-2</sub>)alkylenedioxy;
- (ii) when R<sup>A</sup> is optionally substituted quinazolin-4-yl, cinnolin-4-yl, 1,5-naphthyridin-4-yl, 1,7-naphthyridin-4-yl or 1,8-naphthyridin-4-yl:  
 it is substituted by at least one hydroxy (C<sub>1-6</sub>)alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position as available; or  
 it is substituted by at least one trifluoromethoxy group; or  
 R<sup>1</sup> and R<sup>1a</sup> together represent (C<sub>1-2</sub>)alkylenedioxy;
- R<sup>2</sup> is hydrogen, or (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl optionally substituted with 1 to 3 groups selected from:  
 amino optionally substituted by one or two (C<sub>1-4</sub>)alkyl groups; carboxy; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-4</sub>)alkyl, hydroxy(C<sub>1-4</sub>)alkyl, aminocarbonyl(C<sub>1-4</sub>)alkyl, (C<sub>2-4</sub>)alkenyl, (C<sub>1-4</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-4</sub>)alkenylsulphonyl, (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl or (C<sub>2-4</sub>)alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R<sup>10</sup>; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R<sup>10</sup>; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C<sub>1-4</sub>)alkylthio; trifluoromethyl; hydroxy optionally substituted by (C<sub>1-</sub>

4)alkyl, (C<sub>2-4</sub>)alkenyl, (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl; oxo; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; or (C<sub>1-4</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl;

5

R<sup>3</sup> is hydrogen; or

R<sup>3</sup> is in the 2-, 3- or 4-position and is:

trifluoromethyl; carboxy; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R<sup>10</sup>; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R<sup>10</sup>; or 5-oxo-1,2,4-oxadiazol-3-yl; or


(C<sub>1-4</sub>)alkyl or ethenyl optionally substituted with any of the substituents listed above for R<sup>3</sup> and/or 0 to 2 groups R<sup>12</sup> independently selected from:

halogen; (C<sub>1-6</sub>)alkylthio; trifluoromethyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; (C<sub>2-6</sub>)alkenylcarbonyl; hydroxy optionally substituted by (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylcarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl; amino optionally mono- or disubstituted by (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; oxo; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>2-6</sub>)alkenylsulphonyl; or (C<sub>1-6</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; or

35

R<sup>3</sup> is in the 2-position and is oxo; or

- $R^3$  is in the 3-position and is fluorine, amino optionally substituted by a group selected from hydroxy, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>1-6</sub>)alkyl and (C<sub>2-6</sub>)alkenyl, wherein a (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl moiety may be optionally substituted with up to 2 groups  $R^{12}$ , or hydroxy optionally substituted as described above for  $R^{12}$  hydroxy;
- in addition when  $R^3$  is disubstituted with a hydroxy or amino containing substituent and carboxy containing substituent these may together form a cyclic ester or amide linkage, respectively;
- $R^4$  is a group -U- $R^5$  where
- U is selected from CO, SO<sub>2</sub> and CH<sub>2</sub> and
- $R^5$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



- containing up to four heteroatoms in each ring in which
- at least one of rings (a) and (b) is aromatic;
- $X^1$  is C or N when part of an aromatic ring, or CR<sup>14</sup> when part of a non-aromatic ring;
- $X^2$  is N, NR<sup>13</sup>, O, S(O)<sub>x</sub>, CO or CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may in addition be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring;
- $X^3$  and  $X^5$  are independently N or C;
- $Y^1$  is a 0 to 4 atom linker group each atom of which is independently selected from N, NR<sup>13</sup>, O, S(O)<sub>x</sub>, CO and CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may additionally be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring;
- $Y^2$  is a 2 to 6 atom linker group, each atom of  $Y^2$  being independently selected from N, NR<sup>13</sup>, O, S(O)<sub>x</sub>, CO, CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may additionally be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring;
- each of  $R^{14}$  and  $R^{15}$  is independently selected from: H; (C<sub>1-4</sub>)alkylthio; halo; carboxy(C<sub>1-4</sub>)alkyl; halo(C<sub>1-4</sub>)alkoxy; halo(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl; (C<sub>1-4</sub>)alkoxycarbonyl; formyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; (C<sub>1-4</sub>)alkylcarbonyloxy; (C<sub>1-4</sub>)alkoxycarbonyl(C<sub>1-4</sub>)alkyl; hydroxy; hydroxy(C<sub>1-4</sub>)alkyl; mercapto(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in  $R^3$ ; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl; aryl; aryl(C<sub>1-4</sub>)alkyl; aryl(C<sub>1-4</sub>)alkoxy or

R<sup>14</sup> and R<sup>15</sup> may together represent oxo;

each R<sup>13</sup> is independently H; trifluoromethyl; (C<sub>1-4</sub>)alkyl optionally substituted by hydroxy, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkylthio, halo or trifluoromethyl; (C<sub>2-4</sub>)alkenyl; aryl; aryl (C<sub>1-4</sub>)alkyl; arylcarbonyl; heteroarylcarbonyl; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkylcarbonyl; formyl; (C<sub>1-6</sub>)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl, (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl and optionally further substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl;

each x is independently 0, 1 or 2

n is 0 and AB is NR<sup>11</sup>CO, CO-CR<sup>8</sup>R<sup>9</sup>, CR<sup>6</sup>R<sup>7</sup>-CO, NHR<sup>11</sup>SO<sub>2</sub>, CR<sup>6</sup>R<sup>7</sup>-SO<sub>2</sub> or CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>, provided that R<sup>8</sup> and R<sup>9</sup> are not optionally substituted hydroxy or amino and R<sup>6</sup> and R<sup>8</sup> do not represent a bond:

or n is 1 and AB is NR<sup>11</sup>CO, CO-CR<sup>8</sup>R<sup>9</sup>, CR<sup>6</sup>R<sup>7</sup>-CO, NR<sup>11</sup>SO<sub>2</sub>, CONR<sup>11</sup>, CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>, O-CR<sup>8</sup>R<sup>9</sup> or NR<sup>11</sup>-CR<sup>8</sup>R<sup>9</sup>;

provided that R<sup>6</sup> and R<sup>7</sup>, and R<sup>8</sup> and R<sup>9</sup> are not both optionally substituted hydroxy or amino;

and wherein:

each of R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> is independently selected from: H; (C<sub>1-6</sub>)alkoxy; (C<sub>1-6</sub>)alkylthio; halo; trifluoromethyl; azido; (C<sub>1-6</sub>)alkyl; (C<sub>2-6</sub>)alkenyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; (C<sub>2-6</sub>)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R<sup>3</sup>; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>2-6</sub>)alkenylsulphonyl; or (C<sub>1-6</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; or R<sup>6</sup> and R<sup>8</sup> together represent a bond and R<sup>7</sup> and R<sup>9</sup> are as above defined;

R<sup>10</sup> is selected from (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl and aryl any of which may be optionally substituted by a group R<sup>12</sup> as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; and

R<sup>11</sup> is hydrogen; trifluoromethyl, (C<sub>1-6</sub>)alkyl; (C<sub>2-6</sub>)alkenyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl and optionally further substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl;

or where one of R<sup>3</sup> and R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup> contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage.

This invention also provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.

The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.

The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

20

In one aspect R<sup>A</sup> is not indole or benzofuran.

Preferably Z<sup>2</sup> is three atoms long.

Preferably Z<sup>4</sup> and Z<sup>5</sup> are both carbon.

Preferably Z<sup>1</sup> is three atoms long with carbon joined to Z<sup>3</sup> and with R<sup>1</sup> on the carbon atom joined to Z<sup>3</sup>.

In one preferred aspect, R<sup>A</sup> is aromatic and ring (y) is fused benzene. Preferably (x) is 6-membered containing one or two nitrogen atoms, the remainder being carbon. Most preferably Z<sup>3</sup> is nitrogen and the remainder are carbon or Z<sup>1</sup> is =CH-CH=N- (N attached to Z<sup>5</sup>).

In another preferred aspect, ring (y) is fused pyridin-4-yl (Z<sup>2</sup> is three atoms long, the atom attached to Z<sup>5</sup> in Z<sup>2</sup> is nitrogen and the remainder and Z<sup>4</sup> and Z<sup>5</sup> are carbon), Z<sup>1</sup> is two or three atoms long and Z<sup>3</sup> is a heteroatom such as O or S.

Suitable examples of rings R<sup>A</sup> include optionally substituted isoquinolin-5-yl, quinolin-8-yl, thieno[3,2-b]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl, quinoxalin-5-yl, isoquinolin-8-yl, [1,6]-naphthyridin-4-yl, 1,2,3,4-tetrahydroquinoxalin-5-yl and 1,2-dihydroisoquinoline-8-yl. Most preferably R<sup>A</sup> is optionally 2-substituted-quinolin-8-yl or optionally 3-substituted-quinoxalin-5-yl.

R<sup>13</sup> in rings (x) and (y) is preferably H or (C<sub>1-6</sub>)alkyl.

When  $R^1$  or  $R^{1a}$  is substituted alkoxy it is preferably (C<sub>2-6</sub>)alkoxy substituted by optionally N-substituted amino, or (C<sub>1-6</sub>)alkoxy substituted by piperidyl. Suitable examples of  $R^1$  and  $R^{1a}$  alkoxy include methoxy, trifluoromethoxy, n-propyloxy, isobutyloxy, aminoethyloxy, aminopropyloxy, aminobutyloxy, aminopentyloxy,  
 5 guanidinopropyloxy, piperidin-4-ylmethyloxy or 2-aminocarbonylprop-2-oxy.

Preferably  $R^1$  and  $R^{1a}$  are independently hydrogen, (C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkylthio, (C<sub>1-4</sub>)alkyl, amino(C<sub>3-5</sub>)alkyloxy, nitro, cyano, carboxy, hydroxymethyl or halogen; more preferably hydrogen, methoxy, methyl, cyano, halogen or amino(C<sub>3-5</sub>)alkyloxy. Ring  $R^A$  is preferably substituted by one group  $R^1$ . Most preferably  $R^1$  is H,  
 10 methoxy, methyl, cyano or halogen and  $R^{1a}$  is H. Halogen is preferably chloro or fluoro.

Preferably n is 0.

$R^2$  is preferably hydrogen; (C<sub>1-4</sub>)alkyl substituted with carboxy, optionally substituted hydroxy, optionally substituted aminocarbonyl, optionally substituted amino or (C<sub>1-4</sub>)alkoxycarbonyl; or (C<sub>2-4</sub>)alkenyl substituted with (C<sub>1-4</sub>)alkoxycarbonyl or  
 15 carboxy. More preferred groups for  $R^2$  are hydrogen, carboxymethyl, hydroxyethyl, aminocarbonylmethyl, ethoxycarbonylmethyl, ethoxycarbonylallyl and carboxyallyl, most preferably hydrogen.

Preferred examples of  $R^3$  include hydrogen; optionally substituted hydroxy; optionally substituted amino; halogen; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkyl; ethenyl; optionally substituted 1-hydroxy-(C<sub>1-4</sub>)alkyl; optionally substituted aminocarbonyl; carboxy(C<sub>1-4</sub>)alkyl; optionally substituted aminocarbonyl(C<sub>1-4</sub>)alkyl; cyano(C<sub>1-4</sub>)alkyl; optionally substituted 2-oxo-oxazolidinyl and optionally substituted 2-oxo-oxazolidinyl(C<sub>1-4</sub>)alkyl). More preferred  $R^3$  groups are hydrogen; CONH<sub>2</sub>; 1-hydroxyalkyl e.g. CH<sub>2</sub>OH, CH(OH)CH<sub>2</sub>CN; CH<sub>2</sub>CO<sub>2</sub>H; CH<sub>2</sub>CONH<sub>2</sub>;  
 20 CONHCH<sub>2</sub>CONH<sub>2</sub>; 1,2-dihydroxyalkyl e.g. CH(OH)CH<sub>2</sub>OH; CH<sub>2</sub>CN; 2-oxo-oxazolidin-5-yl, 2-oxo-oxazolidin-5-yl(C<sub>1-4</sub>)alkyl; optionally substituted hydroxy; optionally substituted amino; and halogen, in particular fluoro. Most preferably  $R^3$  is hydrogen, hydroxy or fluoro.

$R^3$  is preferably in the 3- or 4-position.

30 When  $R^3$  is in the 3-position, preferably it is trans to (NR<sup>2</sup>)R<sup>4</sup> and has *R* stereochemistry or is cis to NR<sup>2</sup>R<sup>4</sup> and has *S* stereochemistry.

When  $R^3$  and R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup> together form a cyclic ester or amide linkage, it is preferred that the resulting ring is 5-7 membered. It is further preferred that the group A or B which does not form the ester or amide linkage is CH<sub>2</sub>.

35 Preferably n=0.

In one aspect, CR<sup>6</sup>R<sup>7</sup> is CH<sub>2</sub>, CHOH, CH(NH<sub>2</sub>), C(Me)(OH) or CH(Me) and CR<sup>8</sup>R<sup>9</sup> is CH<sub>2</sub>.



When A is CH(OH) the R-stereochemistry is preferred.

Preferably A is NH, NCH<sub>3</sub>, CH<sub>2</sub>, CHOH, CH(NH<sub>2</sub>), C(Me)(OH) or CH(Me).

Preferably B is CH<sub>2</sub> or CO.

Preferably A-B is CH<sub>2</sub>-CH<sub>2</sub>, CHOH-CH<sub>2</sub>, NR<sup>11</sup>-CH<sub>2</sub> or NR<sup>11</sup>-CO.

- 5 Particularly preferred are those compounds where n=0, A and B are both CH<sub>2</sub>, A is NH and B is CO, or A is CHOH and B is CH<sub>2</sub>, when more preferably A is the *R*-isomer of CHOH.

Preferably R<sup>11</sup> is hydrogen or (C<sub>1-4</sub>)alkyl e.g. methyl, more preferably hydrogen.

U is most preferably CH<sub>2</sub>.

- 10 Preferably R<sup>5</sup> is an aromatic heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR<sup>13</sup> in which preferably Y<sup>2</sup> contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded to X<sup>3</sup>.

- Alternatively and preferably the heterocyclic ring (A) has ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non aromatic and Y<sup>2</sup>  
 15 has 3-5 atoms, more preferably 4 atoms, including a heteroatom bonded to X<sup>5</sup> selected from O, S or NR<sup>13</sup>, where R<sup>13</sup> is other than hydrogen, and NHCO bonded via N to X<sup>3</sup>, or O bonded to X<sup>3</sup>. The ring (a) preferably contains aromatic nitrogen, and more preferably ring (a) is pyridine. Examples of rings (A) include optionally substituted:

- 20 (a) and (b) aromatic

- 1H-pyrrolo[2,3-b]-pyridin-2-yl, 1H-pyrrolo[3,2-b]-pyridin-2-yl, 3H-imidazo[4,5-b]-pyridin-2-yl, 3H-quinazolin-4-one-2-yl, benzimidazol-2-yl, benzo[1,2,3]-thiadiazol-5-yl, benzo[1,2,5]-oxadiazol-5-yl, benzofur-2-yl, benzothiazol-2-yl, benzo[b]thiophen-2-yl, benzoxazol-2-yl, chromen-4-one-3-yl, imidazo[1,2-a]pyridin-2-yl, imidazo-[1,2-a]-  
 25 pyrimidin-2-yl, indol-2-yl, indol-6-yl, isoquinolin-3-yl, [1,8]-naphthyridine-3-yl, oxazolo[4,5-b]-pyridin-2-yl, quinolin-2-yl, quinolin-3-yl, quinoxalin-2-yl, indan-2-yl, naphthalen-2-yl, 1,3-dioxo-indol-2-yl, benzimidazol-2-yl, benzothiophen-2-yl, 1H-benzotriazol-5-yl, 1H-indol-5-yl, 3H-benzooxazol-2-one-6-yl, 3H-benzooxazol-2-thione-6-yl, 3H-benzothiazol-2-one-5-yl, 3H-quinazolin-4-one-2-yl, 3H-quinazolin-4-one-6-yl,  
 30 4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl, benzo[1,2,3]thiadiazol-6-yl, benzo[1,2,5]thiadiazol-5-yl, benzo[1,4]oxazin-2-one-3-yl, benzothiazol-5-yl, benzothiazol-6-yl, cinnolin-3-yl, imidazo[1,2-a]pyridazin-2-yl, imidazo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyrazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyrimidin-6-yl, pyrazolo[5,1-c][1,2,4]triazin-3-yl, pyrido[1,2-a]pyrimidin-4-one-2-yl, pyrido[1,2-a]pyrimidin-4-one-3-yl, quinazolin-2-yl, quinoxalin-6-yl, thiazolo[3,2-a]pyrimidin-5-one-7-yl, thiazolo[5,4-b]pyridin-2-yl, thieno[3,2-b]pyridin-6-yl, thiazolo[5,4-b]pyridin-6-yl, 4-

oxo-4H-pyrido[1,2-a]pyrimidin-2-yl, 1-oxo-1,2-dihydro-isoquinolin-3-yl, thiazolo[4,5-b]pyridin-5-yl, [1,2,3]thiadiazolo[5,4-b]pyridin-6-yl, 2H-isoquinolin-1-one-3-yl

(a) is non aromatic

- 5 (2S)-2,3-dihydro-1H-indol-2-yl, (2S)-2,3-dihydro-benzo[1,4]dioxine-2-yl, 3-(R,S)-3,4-dihydro-2H-benzo[1,4]thiazin-3-yl, 3-(R)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl, 3-(S)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl, 2,3-dihydro-benzo[1,4]dioxan-2-yl, 3-substituted-3H-quinazolin-4-one-2-yl,

10 (b) is non aromatic

- 1,1,3-trioxo-1,2,3,4-tetrahydro-1<sup>6</sup>-benzo[1,4]thiazin-6-yl, benzo[1,3]dioxol-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2-oxo-2,3-dihydro-benzooxazol-6-yl, 3-substituted-3H-benzooxazol-2-one-6-yl, 3-substituted-3H-benzooxazole-2-thione-6-yl, 3-substituted-3H-benzothiazol-2-one-6-yl, 4H-benzo[1,4]oxazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl), 4H-benzo[1,4]thiazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl), 4H-benzo[1,4]oxazin-3-one-7-yl, 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine-7-yl, 5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidin-6-yl, benzo[1,3]dioxol-5-yl, 1H-pyrido[2,3-b][1,4]thiazin-2-one-7-yl (2-oxo-2,3-dihydro-1H-pyrido[2,3-b]thiazin-7-yl), 2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl, 2-oxo-2,3-dihydro-1H-pyrido[3,4-b]thiazin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl, 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[1,4]thiazin-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl, 3,4-dihydro-1H-quinolin-2-one-7-yl, 3,4-dihydro-1H-quinoxalin-2-one-7-yl, 6,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-5-one-2-yl, 5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl, 2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-6-yl, 6-oxo-6,7-dihydro-5H-8-thia-1,2,5-triaza-naphthalen-3-yl, 2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yl, 2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl, 6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-yl.

- 30 R<sup>13</sup> is preferably H if in ring (a) or in addition (C<sub>1-4</sub>)alkyl such as methyl or isopropyl when in ring (b). More preferably, in ring (b) R<sup>13</sup> is H when NR<sup>13</sup> is bonded to X<sup>3</sup> and (C<sub>1-4</sub>)alkyl when NR<sup>13</sup> is bonded to X<sup>5</sup>.

- R<sup>14</sup> and R<sup>15</sup> are preferably independently selected from hydrogen, halo, hydroxy, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, trifluoromethoxy, nitro, cyano, aryl(C<sub>1-4</sub>)alkoxy and (C<sub>1-4</sub>)alkylsulphonyl. More preferably R<sup>15</sup> is hydrogen.

More preferably each R<sup>14</sup> is selected from hydrogen, chloro, fluoro, hydroxy, methyl, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl. Most preferably R<sup>14</sup> is selected from hydrogen, fluorine or nitro.

Most preferably R<sup>14</sup> and R<sup>15</sup> are each H.

5 Most preferred groups R<sup>5</sup> include:

- [1,2,3]thiadiazolo[5,4-b]pyridin-6-yl
  - 1H-Pyrrolo[2,3-b]pyridin-2-yl
  - 2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl
  - 10 2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl
  - 2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl
  - 2,3-dihydro-benzo[1,4]dioxin-6-yl
  - 2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl
  - 2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl
  - 15 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl
  - 3-Methyl-2-oxo-2,3-dihydro-benzooxazol-6-yl
  - 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl
  - 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl
  - 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl (4H-benzo[1,4] thiazin-3-one-6-yl)
  - 20 4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl
  - 6-nitro-benzo[1,3]dioxol-5-yl
  - 7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl
  - 8-Hydroxy-1-oxo-1,2-dihydro-isoquinolin-3-yl
  - 8-hydroxyquinolin-2-yl
  - 25 benzo[1,2,3]thiadiazol-5-yl
  - benzo[1,2,5]thiadiazol-5-yl
  - benzothiazol-5-yl
  - thiazolo-[5,4-b]pyridin-6-yl
  - 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl
  - 30 7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl
  - 7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl
  - 2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]thiazin-7-yl
- especially
- 35 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl
  - 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl
  - 7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl
  - 7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl

2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl.

When used herein, the term "alkyl" includes groups having straight and branched chains, for instance, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, pentyl and hexyl. The term 'alkenyl' should be interpreted accordingly.

5       Halo or halogen includes fluoro, chloro, bromo and iodo.

Haloalkyl moieties include 1-3 halogen atoms.

Unless otherwise defined, the term "heterocyclic" as used herein includes optionally substituted aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and  
10 sulphur, which rings may be unsubstituted or C-substituted by, for example, up to three groups selected from (C<sub>1-4</sub>)alkylthio; halo; carboxy(C<sub>1-4</sub>)alkyl; halo(C<sub>1-4</sub>)alkoxy; halo(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl; (C<sub>1-4</sub>)alkoxycarbonyl; formyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; (C<sub>1-4</sub>)alkylcarbonyloxy; (C<sub>1-4</sub>)alkoxycarbonyl(C<sub>1-4</sub>)alkyl; hydroxy; hydroxy(C<sub>1-4</sub>)alkyl;  
15 mercapto(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxy; nitro; cyano, carboxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R<sup>3</sup>; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl; optionally substituted aryl, aryl(C<sub>1-4</sub>)alkyl or aryl(C<sub>1-4</sub>)alkoxy and oxo groups.

20       Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such  
25 tautomeric forms are included within the scope of the invention.

Where an amino group forms part of a single or fused non-aromatic heterocyclic ring as defined above suitable optional substituents in such substituted amino groups include H; trifluoromethyl; (C<sub>1-4</sub>)alkyl optionally substituted by hydroxy, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkylthio, halo or trifluoromethyl; (C<sub>2-4</sub>)alkenyl; aryl; aryl (C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkylcarbonyl; formyl; (C<sub>1-6</sub>)alkylsulphonyl; or aminocarbonyl  
30 wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl, (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl and optionally further substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl.

When used herein the term "aryl", includes optionally substituted phenyl and  
35 naphthyl.

Aryl groups may be optionally substituted with up to five, preferably up to three, groups selected from (C<sub>1-4</sub>)alkylthio; halo; carboxy(C<sub>1-4</sub>)alkyl; halo(C<sub>1-4</sub>)alkoxy;

halo(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl; (C<sub>1-4</sub>)alkoxycarbonyl; formyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; (C<sub>1-4</sub>)alkylcarbonyloxy; (C<sub>1-4</sub>)alkoxycarbonyl(C<sub>1-4</sub>)alkyl; hydroxy; hydroxy(C<sub>1-4</sub>)alkyl; mercapto(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl  
 5 optionally substituted as for corresponding substituents in R<sup>3</sup>; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl; phenyl, phenyl(C<sub>1-4</sub>)alkyl or phenyl(C<sub>1-4</sub>)alkoxy

The term "acyl" includes formyl and (C<sub>1-6</sub>)alkylcarbonyl group.


Some of the compounds of this invention may be crystallised or recrystallised  
 10 from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Since the compounds of formula (I) are intended for use in pharmaceutical  
 15 compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the  
 20 compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or pharmaceutically acceptable derivative thereof.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable derivatives.

25 Pharmaceutically acceptable derivatives of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric  
 30 acids. Compounds of formula (I) may also be prepared as the N-oxide. Compounds of formula (I) having a free carboxy group may also be prepared as an *in vivo* hydrolysable ester. The invention extends to all such derivatives.

Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming groups include those forming esters which break down readily in the human  
 35 body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):




5

wherein  $\text{R}^a$  is hydrogen, (C<sub>1-6</sub>) alkyl, (C<sub>3-7</sub>) cycloalkyl, methyl, or phenyl,  $\text{R}^b$  is (C<sub>1-6</sub>) alkyl, (C<sub>1-6</sub>) alkoxy, phenyl, benzyl, (C<sub>3-7</sub>) cycloalkyl, (C<sub>3-7</sub>) cycloalkyloxy, (C<sub>1-6</sub>) alkyl (C<sub>3-7</sub>) cycloalkyl, 1-amino (C<sub>1-6</sub>) alkyl, or 1-(C<sub>1-6</sub> alkyl)amino (C<sub>1-6</sub>) alkyl; or  $\text{R}^a$  and  $\text{R}^b$  together form a 1,2-phenylene group optionally substituted by one or two methoxy groups;  $\text{R}^c$  represents (C<sub>1-6</sub>) alkylene optionally substituted with a methyl or ethyl group and  $\text{R}^d$  and  $\text{R}^e$  independently represent (C<sub>1-6</sub>) alkyl;  $\text{R}^f$  represents (C<sub>1-6</sub>) alkyl;  $\text{R}^g$  represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C<sub>1-6</sub>) alkyl, or (C<sub>1-6</sub>) alkoxy; Q is oxygen or NH;  $\text{R}^h$  is hydrogen or (C<sub>1-6</sub>) alkyl;  $\text{R}^i$  is hydrogen, (C<sub>1-6</sub>) alkyl optionally substituted by halogen, (C<sub>2-6</sub>) alkenyl, (C<sub>1-6</sub>) alkoxycarbonyl, aryl or heteroaryl; or  $\text{R}^h$  and  $\text{R}^i$  together form (C<sub>1-6</sub>) alkylene;  $\text{R}^j$  represents hydrogen, (C<sub>1-6</sub>) alkyl or (C<sub>1-6</sub>) alkoxycarbonyl; and  $\text{R}^k$  represents (C<sub>1-8</sub>) alkyl, (C<sub>1-8</sub>) alkoxy, (C<sub>1-6</sub>) alkoxy(C<sub>1-6</sub>)alkoxy or aryl.

Examples of suitable *in vivo* hydrolysable ester groups include, for example, acyloxy(C<sub>1-6</sub>)alkyl groups such as acetoxymethyl, pivaloyloxymethyl,  $\alpha$ -acetoxylethyl,  $\alpha$ -pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; (C<sub>1-6</sub>)alkoxycarbonyloxy(C<sub>1-6</sub>)alkyl groups, such as ethoxycarbonyloxymethyl,  $\alpha$ -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; di(C<sub>1-6</sub>)alkylamino(C<sub>1-6</sub>)alkyl especially di(C<sub>1-4</sub>)alkylamino(C<sub>1-4</sub>)alkyl groups such as

dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; 2-((C<sub>1-6</sub>)alkoxycarbonyl)-2-(C<sub>2-6</sub>)alkenyl groups such as 2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such as phthalidyl and dimethoxyphthalidyl.

- 5 A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming group is that of the formula:





wherein R<sup>k</sup> is hydrogen, C<sub>1-6</sub> alkyl or phenyl.

- 10 R is preferably hydrogen.

Compounds of formula (I) may also be prepared as the corresponding N-oxides.

- Certain of the compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For example the invention includes compound in which an A-B group CH(OH)-CH<sub>2</sub> is in either isomeric configuration, the *R*-isomer is preferred. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

- In a further aspect of the invention there is provided a process for preparing compounds of formula (I), and pharmaceutically acceptable derivatives thereof, which process comprises reacting a compound of formula (IV) with a compound of formula (V):




- wherein n is as defined in formula (I); Z<sup>1'</sup>, Z<sup>2'</sup>, Z<sup>3'</sup>, R<sup>1'</sup>, and R<sup>3'</sup> are Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>3</sup>, R<sup>1</sup>, and R<sup>3</sup> as defined in formula (I) or groups convertible thereto; Z<sup>4</sup> and Z<sup>5</sup> are as defined in formula (I);

Q<sup>1</sup> is NR<sup>2'</sup>R<sup>4'</sup> or a group convertible thereto wherein R<sup>2'</sup> and R<sup>4'</sup> are R<sup>2</sup> and R<sup>4</sup> as defined in formula (I) or groups convertible thereto and Q<sup>2</sup> is H or R<sup>3'</sup> or Q<sup>1</sup> and Q<sup>2</sup> together form an optionally protected oxo group;

- 30 (i) X is A'-COW, Y is H and n is 0;  
(ii) X is CR<sup>6</sup>=CR<sup>8</sup>R<sup>9</sup>, Y is H and n is 0;

- (iii) X is oxirane, Y is H and n is 0;
- (iv) X is N=C=O and Y is H and n is 0;
- (v) one of X and Y is CO<sub>2</sub>R<sup>Y</sup> and the other is CH<sub>2</sub>CO<sub>2</sub>R<sup>X</sup>;
- (vi) X is CHR<sup>6</sup>R<sup>7</sup> and Y is C(=O)R<sup>9</sup>;
- 5 (vii) X is CR<sup>7</sup>=PR<sup>Z</sup><sub>3</sub> and Y is C(=O)R<sup>9</sup> and n=1;
- (viii) X is C(=O)R<sup>7</sup> and Y is CR<sup>9</sup>=PR<sup>Z</sup><sub>3</sub> and n=1;
- (ix) Y is COW and X is NHR<sup>11'</sup>, NCO or NR<sup>11'</sup>COW and n=0 or 1 or when n=1 X is COW and Y is NHR<sup>11'</sup>, NCO or NR<sup>11'</sup>COW;
- (x) X is NHR<sup>11'</sup> and Y is C(=O)R<sup>8</sup> and n=1;
- 10 (xi) X is NHR<sup>11'</sup> and Y is CR<sup>8</sup>R<sup>9</sup>W and n=1;
- (xii) X is NR<sup>11'</sup>COCH<sub>2</sub>W or NR<sup>11'</sup>SO<sub>2</sub>CH<sub>2</sub>W and Y is H and n=0;
- (xiii) X is CR<sup>6</sup>R<sup>7</sup>SO<sub>2</sub>W and Y is H and n=0;
- (xiv) X is W or OH and Y is CH<sub>2</sub>OH and n is 1;
- (xv) X is NHR<sup>11'</sup> and Y is SO<sub>2</sub>W or X is NR<sup>11'</sup>SO<sub>2</sub>W and Y is H, and n is 0;
- 15 (xvi) X is W and Y is CONHR<sup>11'</sup>;
- (xvii) X is -CH=CH<sub>2</sub> and Y is H and n=0;
- (xviii) X is CH<sub>3</sub> and Y is H and n=0 together with formaldehyde in which W is a leaving group, e.g. halo, methanesulphonyloxy, trifluoromethanesulphonyloxy or imidazolyl; R<sup>X</sup> and R<sup>Y</sup> are (C<sub>1-6</sub>)alkyl; R<sup>Z</sup> is aryl or (C<sub>1-6</sub>)alkyl; A' and NR<sup>11'</sup> are A and NR<sup>11</sup> as defined in formula (I), or groups convertible thereto; and oxirane is:



- wherein R<sup>6</sup>, R<sup>8</sup> and R<sup>9</sup> are as defined in formula (I);
- 25 and thereafter optionally or as necessary converting Q<sup>1</sup> and Q<sup>2</sup> to NR<sup>2'</sup>R<sup>4'</sup>; converting A', Z<sup>1'</sup>, Z<sup>2'</sup>, Z<sup>3'</sup>, R<sup>1'</sup>, R<sup>2'</sup>, R<sup>3'</sup>, R<sup>4'</sup> and NR<sup>11'</sup> to A, Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>3</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and NR<sup>11</sup>; converting A-B to other A-B, interconverting R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and/or R<sup>4</sup>, and/or forming a pharmaceutically acceptable derivative thereof.
  - Process variant (i) initially produces compounds of formula (I) wherein A-B is A'-
  - 30 CO.
  - Process variant (ii) initially produces compounds of formula (I) wherein A-B is CHR<sup>6</sup>-CR<sup>8</sup>R<sup>9</sup>.
  - Process variant (iii) initially produces compounds of formula (I) wherein A-B is CR<sup>6</sup>(OH)-CR<sup>8</sup>R<sup>9</sup>.
  - 35 Process variant (iv) initially produces compounds of formula (I) where A-B is NH-CO.



Process variant (v) initially produces compounds of formula (I) wherein A-B is CO-CH<sub>2</sub> or CH<sub>2</sub>-CO.

Process variant (vi) initially produces compounds of formula (I) wherein A-B is CR<sup>6</sup>R<sup>7</sup>-CR<sup>9</sup>OH.

5        Process variant (vii) and (viii) initially produce compounds of formula (I) wherein A-B is CR<sup>7</sup>=CR<sup>9</sup>.

Process variant (ix) initially produces compounds of formula (I) where A-B is CO-NR<sup>11</sup> or NR<sup>11</sup>-CO.

10       Process variant (x) initially produces compounds of formula (I) wherein A-B is NR<sup>11</sup>-CHR<sup>8</sup>.

Process variant (xi) initially produces compounds of formula (I) wherein A-B is NR<sup>11'</sup>-CR<sup>8</sup>R<sup>9</sup>.

Process variant (xii) initially produces compounds of formula (I) where A-B is NR<sup>11'</sup>-CO or NR<sup>11'</sup>-SO<sub>2</sub> and n=1.

15       Process variant (xiii) initially produces compounds of formula (I) where A-B is CR<sup>6</sup>R<sup>7</sup>-SO<sub>2</sub>.

Process variant (xiv) initially produces compounds of formula (I) wherein A-B is O-CH<sub>2</sub>.

Process variant (xv) initially produces compounds where AB is NR<sup>11</sup>SO<sub>2</sub>.

20       Process variant (xvi) initially produces compounds of formula (I) where A-B is NR<sup>11'</sup>-CO.

Process variants (xvii) and (xviii) initially produce compounds of formula (I) where A-B is -CH<sub>2</sub>-CH<sub>2</sub>-.

25       In process variants (i) and (ix) the reaction is a standard amide or urea formation reaction involving e.g.:

1. Activation of a carboxylic acid (e.g. to an acid chloride, mixed anhydride, active ester, O-acyl-isourea or other species), and treatment with an amine (Ogliaruso, M.A.; Wolfe, J.F. in *The Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Acid Derivatives, Pt. 1* (John Wiley and Sons, 1979), pp 442-8; Beckwith, A.L.J. in *The Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Amides (Ed. Zabricky, J.)* (John Wiley and Sons, 1970), p 73 ff. The acid and amine are preferably reacted in the presence of an activating agent such as 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT) or O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU); or
- 30       2. The specific methods of:
  - a. *in situ* conversion of an acid into the amine component by a modified Curtius reaction procedure (Shioiri, T., Murata, M., Hamada, Y., *Chem. Pharm. Bull.* 1987, 35, 2698)
- 35

b. *in situ* conversion of the acid component into the acid chloride under neutral conditions (Villeneuve, G. B.; Chan, T. H., *Tetrahedron. Lett.* 1997, 38, 6489).

A' may be, for example. protected hydroxymethylene.

The process variant (ii) is a standard addition reaction using methods well known  
5 to those skilled in the art. The process is preferably carried out in a polar organic solvent  
e.g. acetonitrile in the presence of an organic base e.g. triethylamine.

In process variant (iii) the coupling may be effected in a suitable solvent such as  
acetonitrile or dimethylformamide at room temperature in the presence of one equivalent  
of lithium perchlorate as catalyst (general method of J.E. Chateaneuf *et al.*, *J. Org.*  
10 *Chem.*, 56, 5939-5942, 1991) or more preferably with ytterbium triflate in  
dichloromethane. In some cases an elevated temperature such as 40 – 70 °C may be  
beneficial. Alternatively, the piperidine may be treated with a base, such as one  
equivalent of butyl lithium, and the resulting salt reacted with the oxirane in an inert  
solvent such as tetrahydrofuran, preferably at an elevated temperature such as 80°C. Use  
15 of a chiral epoxide will afford single diastereomers. Alternatively, mixtures of  
diastereomers may be separated by preparative HPLC or by conventional resolution  
through crystallisation of salts formed from chiral acids.

The process variant (iv) is a standard urea formation reaction from the reaction of  
an isocyanate with an amine and is conducted by methods well known to those skilled in  
20 the art (for example see March, J; *Advanced Organic Chemistry, Edition 3* (John Wiley  
and Sons, 1985), p802-3). The process is preferably carried out in a polar solvent such as  
N,N-dimethylformamide.

In process variant (v) the process is two step: firstly a condensation using a base,  
preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide,  
25 preferably in an aprotic solvent e.g. ether, THF or benzene; secondly, hydrolysis using an  
inorganic acid, preferably HCl in aqueous organic solvent at 0-100°C. Analogous routes  
are described in DE330945, EP31753, EP53964 and H. Sargent, *J. Am. Chem. Soc.* 68,  
2688-2692 (1946). Similar Claisen methodology is described in Soszko *et. al.*,  
*Pr.Kom.Mat. Przyr.Poznan.Tow.Przyj.Nauk.*, (1962), 10, 15.

30 In process variant (vi) the reaction is carried out in the presence of a base,  
preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt,  
preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C  
(analogous process in Gutswiller *et al.* (1978) *J. Am. Chem. Soc.* 100, 576).

In process variants (vii) and (viii) if a base is used it is preferably NaH, KH, an  
35 alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide  
e.g. di- isopropylamide. An analogous method is described in US 3989691 and M.Gates  
*et. al.* (1970) *J. Amer.Chem.Soc.*, 92, 205, as well as Taylor *et al.* (1972) *JACS* 94, 6218.

In process variant (x) where Y is CHO the reaction is a standard reductive alkylation using, e.g., sodium borohydride or sodium triacetoxyborohydride (Gribble, G. W. in *Encyclopedia of Reagents for Organic Synthesis* (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649).

5       The process variant (xi) is a standard alkylation reaction well known to those skilled in the art, for example where an alcohol or amine is treated with an alkyl halide in the presence of a base (for example see March, J; *Advanced Organic Chemistry, Edition 3* (John Wiley and Sons, 1985), p364-366 and p342-343). The process is preferably carried out in a polar solvent such as N,N-dimethylformamide

10       In process variant (xii) the reaction is an alkylation, examples of which are described in J. Med. chem. (1979) 22(10) 1171-6. The compound of formula (IV) may be prepared from the corresponding compound where X is  $\text{NHR}^{11'}$  by acylation with an appropriate derivative of the acid  $\text{WCH}_2\text{COOH}$  such as the acid chloride or sulphonation with an appropriate derivative of the sulphonic acid  $\text{WCH}_2\text{SO}_3\text{H}$  such as the sulphonyl  
15 chloride.

In process variant (xiii) the reaction is a standard sulphonamide formation reaction well known to those skilled in the art. This may be e.g. the reaction of a sulphonyl halide with an amine.

In process variant (xiv) where X is W such as halogen, methanesulphonyloxy or  
20 trifluoromethanesulphonyloxy, the hydroxy group in Y is preferably converted to an OM group where M is an alkali metal by treatment of an alcohol with a base. The base is preferably inorganic such as NaH, lithium diisopropylamide or sodium. Where X is OH, the hydroxy group in Y is activated under Mitsunobu conditions (Fletcher et.al. J Chem Soc. (1995), 623). Alternatively the  $\text{X}=\text{O}$  and  $\text{Y}=\text{CH}_2\text{OH}$  groups can be reacted directly  
25 by activation with 1,3-dicyclohexylcarbodiimide (DCC) (Chem. Berichte 1962, 95, 2997 or Angewante Chemie 1963 75, 377).

In process variant (xv) the reaction is conducted in the presence of an organic base such as triethylamine or pyridine such as described by Fuhrman et.al., J. Amer. Chem. Soc.; 67, 1245, 1945. The  $\text{X}=\text{NR}^{11'}\text{SO}_2\text{W}$  or  $\text{Y}=\text{SO}_2\text{W}$  intermediates can be  
30 formed from the requisite amine e.g. by reaction with  $\text{SO}_2\text{Cl}_2$  analogously to the procedure described by the same authors Fuhrman et.al., J. Amer. Chem. Soc.; 67, 1245, 1945.

In process variant (xvi) the leaving group W is preferably chloro, bromo or iodo or trifluoromethylsulphonyloxy and the reaction is the palladium catalysed process known as  
35 the "Buchwald" reaction (J. Yin and S. L. Buchwald, Org.Lett., 2000, 2, 1101).

In process variant (xvii) the reaction is the addition of an amine to an olefin which is susceptible to nucleophilic attack.

In process variant (xviii) the reaction is a three component condensation reaction carried out under mildly acidic conditions.

Reduction of a carbonyl group A or B to CHOH can be readily accomplished using reducing agents well known to those skilled in the art, e.g. sodium borohydride in aqueous ethanol or lithium aluminium hydride in ethereal solution. This is analogous to  
5 methods described in EP53964, US384556 and J. Gutzwiller *et al*, *J. Amer. Chem. Soc.*, 1978, 100, 576.

The carbonyl group A or B may be reduced to CH<sub>2</sub> by treatment with a reducing agent such as hydrazine in ethylene glycol, at e.g. 130-160°C, in the presence of  
10 potassium hydroxide.

Reaction of a carbonyl group A or B with an organometallic reagent yields a group where R<sup>6</sup> or R<sup>8</sup> is OH and R<sup>7</sup> or R<sup>9</sup> is alkyl.

A hydroxy group on A or B may be oxidised to a carbonyl group by oxidants well known to those skilled in the art, for example, manganese dioxide, pyridinium  
15 chlorochromate or pyridinium dichromate.

A hydroxyalkyl A-B group CHR<sup>7</sup>CR<sup>9</sup>OH or CR<sup>7</sup>(OH)CHR<sup>9</sup> may be dehydrated to give the group CR<sup>7</sup>=CR<sup>9</sup> by treatment with an acid anhydride such as acetic anhydride.


Methods for conversion of CR<sup>7</sup>=CR<sup>9</sup> by reduction to CHR<sup>7</sup>CHR<sup>9</sup> are well known to those skilled in the art, for example using hydrogenation over palladium on  
20 carbon as catalyst. Methods for conversion of CR<sup>7</sup>=CR<sup>9</sup> to give the A-B group CR<sup>7</sup>(OH)CHR<sup>9</sup> or CHR<sup>7</sup>CR<sup>9</sup>OH are well known to those skilled in the art for example by epoxidation and subsequent reduction by metal hydrides, hydration, hydroboration or oxymercuration.

An amide carbonyl group may be reduced to the corresponding amine using a  
25 reducing agent such as lithium aluminium hydride.

A hydroxy group in A or B may be converted to azido by activation and displacement e.g. under Mitsunobu conditions using hydrazoic acid or by treatment with diphenylphosphorylazide and base, and the azido group in turn may be reduced to amino  
by hydrogenation.

30 An example of a group Q<sup>1</sup> convertible to NR<sup>2</sup> R<sup>4</sup> is NR<sup>2</sup>'R<sup>4</sup>' or halogen. Halogen may be displaced by an amine HNR<sup>2</sup>'R<sup>4</sup>' by a conventional alkylation.

When Q<sup>1</sup> Q<sup>2</sup> together form a protected oxo group this may be an acetal such as ethylenedioxy which can subsequently be removed by acid treatment to give a compound of formula (VI):



wherein the variables are as described for formula (I)

The ketone of formula (VI) is reacted with an amine  $\text{HNR}^2\text{R}^4$  by conventional reductive alkylation as described above for process variant (x).

- 5        Examples of groups  $\text{Z}^1$ ,  $\text{Z}^2$  and  $\text{Z}^3$  convertible to  $\text{Z}^1$ ,  $\text{Z}^2$  and  $\text{Z}^3$  include  $\text{CR}^1$  or  $\text{CR}^1\text{CR}^{1a'}$  where  $\text{R}^1$  and  $\text{R}^{1a'}$  are groups convertible to  $\text{R}^1$  and  $\text{R}^{1a}$ .  $\text{Z}^1$ ,  $\text{Z}^2$  and  $\text{Z}^3$  are preferably  $\text{Z}^1$ ,  $\text{Z}^2$  and  $\text{Z}^3$ .

- $\text{R}^{1a'}$ ,  $\text{R}^1$  and  $\text{R}^2$  are preferably  $\text{R}^{1a}$ ,  $\text{R}^1$  and  $\text{R}^2$ .  $\text{R}^2$  is preferably hydrogen.  $\text{R}^3$  is  $\text{R}^3$  or more preferably hydrogen, vinyl, alkoxycarbonyl or carboxy.  $\text{R}^4$  is  $\text{R}^4$  or more  
 10        preferably H or an N-protecting group such as t-butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl.

- Conversions of  $\text{R}^1$ ,  $\text{R}^{1a'}$ ,  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  and interconversions of  $\text{R}^1$ ,  $\text{R}^{1a}$ ,  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  are conventional. In compounds which contain an optionally protected hydroxy group, suitable conventional hydroxy protecting groups which may be removed  
 15        without disrupting the remainder of the molecule include acyl and alkylsilyl groups. N-protecting groups are removed by conventional methods.

- For example  $\text{R}^1$  methoxy is convertible to  $\text{R}^1$  hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland *et al*, *J. Amer. Chem. Soc.*, 1973, 7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative  
 20        bearing a leaving group such as halide and a protected amino, piperidyl, amidino or guanidino group or group convertible thereto, yields, after conversion/deprotection,  $\text{R}^1$  alkoxy substituted by optionally N-substituted amino, piperidyl, guanidino or amidino.

- $\text{R}^3$  alkenyl is convertible to hydroxyalkyl by hydroboration using a suitable reagent such as 9-borabicyclo[3.3.1]nonane, epoxidation and reduction or  
 25        oxymercuration.

- $\text{R}^3$  1,2-dihydroxyalkyl can be prepared from  $\text{R}^3$  alkenyl using osmium tetroxide or other reagents well known to those skilled in the art (see Advanced Organic Chemistry, *Ed. March, J.*, John Wiley and Sons, 1985, p 732-737 and refs. cited therein) or epoxidation followed by hydrolysis (see Advanced Organic Chemistry, *Ed. March, J.*  
 30        John Wiley and Sons, 1985, p 332,333 and refs. cited therein).

$\text{R}^3$  vinyl can be chain extended by standard homologation, e.g. by conversion to hydroxyethyl followed by oxidation to the aldehyde, which is then subjected to a Wittig reaction.

Opening an epoxide-containing  $R^3$  group with cyanide anion yields a  $CH(OH)-CH_2CN$  group.

Opening an epoxide-containing  $R^3$  group with azide anion yields an azide derivative which can be reduced to the amine. Conversion of the amine to a carbamate is  
5 followed by ring closure with base to give the 2-oxo-oxazolidinyl containing  $R^3$  group.

Substituted 2-oxo-oxazolidinyl containing  $R^3$  groups may be prepared from the corresponding aldehyde by conventional reaction with a glycine anion equivalent, followed by cyclisation of the resulting amino alcohol (M. Grauert *et al*, *Ann. Chem.*, 1985, 1817; Rozenberg *et al*, *Angew. Chem. Int. Ed. Engl.*, 1994, 33(1), 91). The  
10 resulting 2-oxo-oxazolidinyl group contains a carboxy group which can be converted to other  $R^{10}$  groups by standard procedures.

Carboxy groups within  $R^3$  may be prepared by Jones' oxidation of the corresponding alcohols  $CH_2OH$  using chromic acid and sulphuric acid in water/methanol (E.R.H. Jones *et al*, *J. Chem. Soc.*, 1946, 39). Other oxidising agents may be used for this  
15 transformation such as sodium periodate catalysed by ruthenium trichloride (G.F. Tutwiler *et al*, *J. Med. Chem.*, 1987, 30(6), 1094), chromium trioxide-pyridine (G. Just *et al*, *Synth. Commun.*, 1979, 9(7), 613), potassium permanganate (D.E. Reedich *et al*, *J. Org. Chem.*, 1985, 50(19), 3535), and pyridinium chlorochromate (D. Askin *et al*, *Tetrahedron Lett.*, 1988, 29(3), 277).

20 The carboxy group may alternatively be formed in a two stage process, with an initial oxidation of the alcohol to the corresponding aldehyde using for instance dimethyl sulphoxide activated with oxalyl chloride (N.Cohen *et al*, *J. Am. Chem. Soc.*, 1983, 105, 3661) or dicyclohexylcarbodiimide (R.M.Wengler, *Angew. Chim. Int. Ed. Eng.*, 1985, 24(2), 77), or oxidation with tetrapropylammonium perruthenate (Ley *et al*, *J. Chem. Soc. Chem Commun.*, 1987, 1625). The aldehyde may then be separately oxidised to the  
25 corresponding acid using oxidising agents such as silver (II) oxide (R.Grigg *et al*, *J. Chem. Soc. Perkin1*, 1983, 1929), potassium permanganate (A.Zurcher, *Helv. Chim. Acta.*, 1987, 70 (7), 1937), sodium periodate catalysed by ruthenium trichloride (T.Sakata *et al*, *Bull. Chem. Soc. Jpn.*, 1988, 61(6), 2025), pyridinium chlorochromate (R.S.Reddy *et al*, *Synth. Commun.*, 1988, 18(51), 545) or chromium trioxide (R.M.Coates *et al*, *J. Am. Chem. Soc.*, 1982, 104, 2198).  
30

An  $R^3 CO_2H$  group may also be prepared from oxidative cleavage of the corresponding diol,  $CH(OH)CH_2OH$ , using sodium periodate catalysed by ruthenium trichloride with an acetonitrile-carbontetrachloride-water solvent system (V.S.Martin *et al*, *Tetrahedron Letters*, 1988, 29(22), 2701).  
35

Other routes to the synthesis of carboxy groups within  $R^3$  are well known to those skilled in the art.


$R^3$  groups containing a cyano or carboxy group may also be prepared by conversion of an alcohol to a suitable leaving group such as the corresponding tosylate by reaction with para-toluenesulphonyl chloride (M.R. Bell, *J. Med. Chem.*, 1970, **13**, 389), or the iodide using triphenylphosphine, iodine, and imidazole (G. Lange, *Synth. Commun.*, 1990, **20**, 1473). The second stage is the displacement of the leaving group with cyanide anion (L.A. Paquette *et al*, *J. Org. Chem.*, 1979, **44**(25), 4603; P.A. Grieco *et al*, *J. Org. Chem.*, 1988, **53**(16), 3658. Finally acidic hydrolysis of the nitrile group gives the desired acids (H. Rosemeyer *et al*, *Heterocycles*, 1985, **23** (10), 2669). The hydrolysis may also be carried out with base e.g. potassium hydroxide (H. Rapoport, *J. Org. Chem.*, 1958, **23**, 248) or enzymatically (T. Beard *et al*, *Tetrahedron Asymmetry*, 1993, **4** (6), 1085).

$R^3$  cis or trans hydroxy may be introduced by the methods of van Deale *et al.*, *Drug Development Research* 8:225-232 (1986) or *Heterocycles* 39(1), 163-170 (1994). For trans hydroxy, a suitable method converts N-protected tetrahydropyridine to the epoxide by treatment with meta-chloroperoxybenzoic acid, followed by opening of the epoxide with a suitable amine  $NR^{2'}R^{4'}$ .  $R^{3'}$  hydroxy may then be converted to optionally substituted amino via preparation of the  $R^{3'}$  amino derivative by standard transformations such as a Mitsunobu reaction (for example as reviewed in Misunobu, *Synthesis*, (1981), **1**), for example with succinimide in the presence of diethylazodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine. Removal of the phthaloyl group, for example by treatment with methylhydrazine, affords the  $R^{3'}$  amine. Optional substitution may then be introduced by standard methods for amine substitution well known to those skilled in the art.

$R^3$  4-CF<sub>3</sub> may be introduced by the following scheme I:

25

Scheme I



(a) (Boc)<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>; (b) LDA, then CF<sub>3</sub>-X; (c) NaOH, H<sub>2</sub>O, EtOH; (d) DPPA, Et<sub>3</sub>N, toluene, then BnOH; (e) H<sub>2</sub>, Pd/C, EtOH.


Commercially-available ethyl isonipecotate (I-1) reacts with an appropriate acylating agent, preferably di-*tert*-butyl dicarbonate, to afford the protected derivative I-2. Typical solvents for this reaction include CH<sub>2</sub>Cl<sub>2</sub>, THF, or DMF. The protecting group for the amine must be compatible with subsequent chemistry, and must be readily removable when desired. Methods for the protection of amines are well-known to those of skill in the art, and are described in standard reference volumes, such as Greene "Protective Groups in Organic Synthesis" (published by Wiley-Interscience). Alkylation of I-2 can be accomplished by reaction with an appropriate base, typically LDA or LiN(TMS)<sub>2</sub>, in an aprotic solvent, usually THF or DME, followed by trapping of the enolate with an appropriate electrophile, to afford I-3. Trifluoromethyl iodide (CF<sub>3</sub>I) or *S*-(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate are typically preferred as electrophilic trifluoromethylating reagents. The ethyl ester of I-3 is hydrolyzed using aqueous base, for example, LiOH in aqueous THF or NaOH in aqueous methanol or ethanol, and the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HCl, to afford the carboxylic acid I-4. Curtius-type rearrangement of I-4 gives an intermediate isocyanate, which typically is not isolated, but rather is reacted *in situ* with an appropriate alcohol, such as benzyl alcohol, to give I-5. Diphenylphosphoryl azide in the presence of an amine base, generally triethylamine or diisopropylethylamine (Hunig's base), is the preferred reagent combination for effecting the Curtius-type rearrangement of I-4, but more classical conditions, such as formation of the acid chloride, reaction with azide anion, and warming of the acyl azide, can also be used. The benzyloxycarbonyl group in I-5 is removed by hydrogenolysis in the presence of a palladium catalyst, typically palladium on activated charcoal, in a suitable solvent, usually EtOH, MeOH, EtOAc, or mixtures thereof, to give amine I-6.

25

R<sup>3</sup> 2-CF<sub>3</sub> may be introduced by the following scheme II:

Scheme II






- (a) 1-methoxy-3-(trimethylsilyloxy)-1,3-butadiene,  $\text{ZnCl}_2$ ,  $\text{CH}_3\text{CN}$ ; (b) separate diastereomers; (c) L-Selectride® (lithium tri-*sec*-butylborohydride), THF then pyridinium dichromate,  $\text{CH}_2\text{Cl}_2$  as necessary; (d)  $\text{NH}_2\text{OCH}_3$ , *p*-TsOH, toluene; or  $\text{NH}_2\text{OCH}_3$ , NaOAc, EtOH; (e)  $\text{LiAlH}_4$ , THF; or Al-Ni, 2N NaOH, EtOH; (f)  $(\text{Boc})_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$  or THF or DMF; (g)  $\text{H}_2$ , Pd/C, EtOH.

Imine **II-1**, prepared in standard fashion by acid-catalyzed reaction of trifluoroacetaldehyde ethyl hemiacetal and  $(R)$ -(+)- $\alpha$ -methylbenzylamine, reacts with a silyoxydiene, for example 1-methoxy-3-(trimethylsilyloxy)-1,3-butadiene, in a Diels-Alder reaction to afford piperidone **II-2**. The reaction is conducted in a neutral solvent such as  $\text{CH}_3\text{CN}$ , THF, or  $\text{CH}_2\text{Cl}_2$ , and oftentimes is mediated by a Lewis acid such as  $\text{ZnCl}_2$ . Diastereomers are best separated at this point. The enone **II-2** is reduced to the corresponding ketone **II-3** by reaction with L-Selectride® in a suitable solvent, generally THF or DME, and the ketone is converted to an oxime derivative under standard conditions well-known to those of skill in the art. Reduction of the oxime derivative under standard conditions ( $\text{LiAlH}_4$ ) gives a mixture of diastereomeric amines from which the amine **II-5** can be isolated. The amine is protected with an appropriate protecting group, preferably a *tert*-butyl carbamate (see Scheme I), to afford **II-6**. The  $\alpha$ -methylbenzyl group of **II-6** is removed by hydrogenolysis in the presence of a palladium catalyst, typically palladium on activated charcoal, in a suitable solvent, usually EtOH, MeOH, EtOAc, or mixtures thereof, to give amine **II-7**.

R<sup>3</sup> 3-CF<sub>3</sub> may be introduced by the following scheme III:

Scheme III



5


(a) TMSCl, Et<sub>3</sub>N, DMF; (b) CF<sub>3</sub>-X, DMF; (c) (*R*)-(+)- $\alpha$ -methylbenzylamine, *p*-TsOH, toluene; (d) NaBH<sub>4</sub>, EtOH; (e) separate diastereomers; (f) H<sub>2</sub>, Pd/C, EtOH.

The commercially-available ketone **III-1** is converted to the corresponding silyl enol ether **III-2** by reaction with a silylating reagent, such as a trimethylsilyl chloride or trimethylsilyl triflate, in the presence of an amine base, typically triethylamine, in a suitable solvent, such as diethyl ether, THF, DMF, or mixtures thereof. The silyl enol ether **III-2** reacts with an electrophilic trifluoromethylating reagent, such as trifluoromethyl iodide (CF<sub>3</sub>I) or more preferably *S*-(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate (see *Tet. Lett.* **1990**, *31*, 3579-3582)), in an appropriate solvent, such as THF, DMF, or mixtures thereof, to afford the  $\alpha$ -trifluoromethyl ketone **III-3**. Ketone **III-3** reacts with a chiral amine, for instance (*R*)-(+)- $\alpha$ -methylbenzylamine, under standard acidic catalysis, to afford the imine derivative **III-4**, which can be reduced to afford amine **III-5**. This type of reduction is typically conducted using sodium borohydride, sodium cyanoborohydride or sodium (triacetoxy)borohydride, in an appropriate solvent, such as EtOH, MeOH, THF, CH<sub>2</sub>Cl<sub>2</sub>, ClCH<sub>2</sub>CH<sub>2</sub>Cl, or mixtures thereof. Diastereomers are best separated at this point. The  $\alpha$ -methylbenzyl group of **III-5** is removed by hydrogenolysis in the presence of a palladium catalyst, typically palladium on activated charcoal, in a suitable solvent, usually EtOH, MeOH, EtOAc, or mixtures thereof, to give amine **III-6**.

25

R<sup>3</sup> 2-oxo may be introduced by the following scheme IV:

Scheme IV




(a) NaH, THF, 0 °C to RT; (b) 10% Pd/C, H<sub>2</sub>, MeOH.

- 5            (R,S)-4-(Dibenzylamino)piperidin-2-one (IV-2, Homo-Freidinger Lactam, prepared from (R,S)-aspartic acid according to the procedure of Weber and Gmeiner, *Synlett*, 1998, 885-887) reacts with an appropriate epoxide, for instance 6-methoxy-4-(R)-oxiranylquinoline (VI-1) or 6-methoxy-4-(R)-oxiranyl-[1,5]naphthyridine, to afford the adduct IV-3. The reaction is mediated by a strong base, preferably sodium hydride,
- 10 which is used to deprotonate IV-2, and is typically conducted in a polar, aprotic solvent, such as THF, DMF, or mixtures thereof. The benzyl groups in IV-3 are removed by hydrogenolysis in the presence of a palladium catalyst, typically palladium on activated charcoal, in a suitable solvent, usually EtOH, MeOH, EtOAc, or mixtures thereof, to give amine IV-4.

15

R<sup>3</sup> 3-F may be introduced by the following scheme V:

Scheme V



- 5 (a) TMSCl, Et<sub>3</sub>N, DMF, 80 °C; (b) Selectfluor™, CH<sub>3</sub>CN; (c) benzylamine, 1,2-dichloroethane, Na(OAc)<sub>3</sub>BH; (d) separate diastereomers; (e) 10% Pd/C, H<sub>2</sub>, HCl, EtOH.

The trimethylsilyl enol ether (V-2), prepared from commercially-available *N*-(*tert*-butoxycarbonyl)piperidone (V-1) as described in Scheme III, reacts with an electrophilic fluorinating reagent, preferably Selectfluor™ (1-chloromethyl-4-fluoro-1,4-diazabicyclo[2.2.2]octane bis(tetrafluoroborate), in a neutral solvent such as CH<sub>3</sub>CN, to afford the  $\alpha$ -fluoro ketone V-3. Reductive amination of V-3 with benzylamine according to the procedures described in Schemes I and III gives the expected 4-aminobenzyl-3-fluoro-*N*-(*tert*-butoxycarbonyl)piperidine derivatives V-4 and V-5 as a mixture of *cis*- and *trans*-isomers in an 8:1 ratio. These diastereomers are separable by chromatography on silica gel. The predominate *cis*-mixture of enantiomers is debenzylated by catalytic hydrogenation as described in Scheme II, to give the amino derivative V-6.

Other functional groups in R<sup>3</sup> may be obtained by conventional conversions of hydroxy, carboxy or cyano groups.

20 Tetrazoles are conveniently prepared by reaction of sodium azide with the cyano group (e.g. F. Thomas *et al*, *Bioorg. Med. Chem. Lett.*, 1996, 6(6), 631; K. Kubo *et al*, *J. Med. Chem.*, 1993, 36, 2182) or by reaction of azidotri-*n*-butyl stannane with the cyano group followed by acidic hydrolysis (P.L. Ornstein, *J. Org. Chem.*, 1994, 59, 7682 and *J. Med. Chem.*, 1996, 39 (11), 2219).

25 The 3-hydroxy-3-cyclobutene-1,2-dione-4-yl group (e.g. R.M. Soll, *Bioorg. Med. Chem. Lett.*, 1993, 3(4), 757 and W.A. Kinney, *J. Med. Chem.*, 1992, 35(25), 4720) can be prepared by the following sequence:- (1) a compound where R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>CHO (*n* = 0,1,2) is treated with triethylamine, carbon tetrabromide/triphenylphosphine to give initially (CH<sub>2</sub>)<sub>n</sub>CH=CHBr; (2) dehydrobromination of this intermediate to give the corresponding bromoethyne derivative (CH<sub>2</sub>)<sub>n</sub>C≡CBr (for this 2 stage sequence see D. Grandjean *et al*, *Tetrahedron Lett.*, 1994, 35(21), 3529); (3) palladium-catalysed coupling

of the bromoethyne with 4-(1-methylethoxy)-3-(tri-n-butylstannyl)cyclobut-3-ene-1,2-dione (Liebeskind *et al*, *J. Org. Chem.*, 1990, 55, 5359); (4) reduction of the ethyne moiety to -CH<sub>2</sub>CH<sub>2</sub>- under standard conditions of hydrogen and palladium on charcoal catalysis (see Howard *et al*, *Tetrahedron*, 1980, 36, 171); and finally (4) acidic hydrolysis  
5 of the methyl ethoxyester to generate the corresponding 3-hydroxy-3-cyclobutene-1,2-dione group (R.M. Soll, *Bioorg. Med. Chem. Lett.*, 1993, 3(4), 757).

The tetrazol-5-ylaminocarbonyl group may be prepared from the corresponding carboxylic acid and 2-aminotetrazole by dehydration with standard peptide coupling agents such as 1,1'-carbonyldiimidazole (P.L. Ornstein *et al*, *J. Med Chem*, 1996, 39(11),  
10 2232).

The alkyl- and alkenyl-sulphonylcarboxamides are similarly prepared from the corresponding carboxylic acid and the alkyl- or alkenyl-sulphonamide by dehydration with standard peptide coupling agents such as 1,1'-carbonyldiimidazole (P.L. Ornstein *et al*, *J. Med. Chem.*, 1996, 39(11), 2232).

15 The hydroxamic acid groups are prepared from the corresponding acids by standard amide coupling reactions e.g. N.R. Patel *et al*, *Tetrahedron*, 1987, 43(22), 5375.

2,4-Thiazolidinedione groups may prepared from the aldehydes by condensation with 2,4-thiazolidinedione and subsequent removal of the olefinic double bond by hydrogenation.

20 The preparation of 5-oxo-1,2,4-oxadiazoles from nitriles is described by Y. Kohara *et al*, *Bioorg. Med. Chem. Lett.*, 1995, 5(17), 1903.

1,2,4-Triazol-5-yl groups may be prepared from the corresponding nitrile by reaction with an alcohol under acid conditions followed by reaction with hydrazine and then an R<sup>10</sup>-substituted activated carboxylic acid (see J.B. Polya in "Comprehensive  
25 Heterocyclic Chemistry" Edition 1, p762, Ed A.R. Katritzky and C.W. Rees, Pergamon Press, Oxford, 1984 and J.J. Ares *et al*, *J. Heterocyclic Chem.*, 1991, 28(5), 1197).

Other substituents on R<sup>3</sup> alkyl or alkenyl may be interconverted by conventional methods, for example hydroxy may be derivatised by esterification, acylation or etherification. Hydroxy groups may be converted to halogen, thiol, alkylthio, azido,  
30 alkylcarbonyl, amino, aminocarbonyl, oxo, alkylsulphonyl, alkenylsulphonyl or aminosulphonyl by conversion to a leaving group and substitution by the required group or oxidation as appropriate or reaction with an activated acid, isocyanate or alkoxyisocyanate. Primary and secondary hydroxy groups can be oxidised to an aldehyde or ketone respectively and alkylated with a suitable agent such as an organometallic  
35 reagent to give a secondary or tertiary alcohol as appropriate. A carboxylate group may be converted to an hydroxymethyl group by reduction of an ester of this acid with a suitable reducing agent such as lithium aluminium hydride.

An  $\text{NH}_2$  substituent on piperidine is converted to  $\text{NR}^2\text{R}^4$  by conventional means such as amide or sulphonamide formation with an acyl derivative  $\text{R}^5\text{COW}$  or  $\text{R}^5\text{SO}_2\text{W}$ , for compounds where U is CO or  $\text{SO}_2$  or, where U is  $\text{CH}_2$ , by alkylation with an alkyl halide  $\text{R}^5\text{CH}_2$ -halide in the presence of base, acylation/reduction with an acyl derivative  $\text{R}^5\text{COW}$  or reductive alkylation with an aldehyde  $\text{R}^5\text{CHO}$ .

Where one of  $\text{R}^3$  and  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  or  $\text{R}^9$  contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage. This linkage may form spontaneously during coupling of the compound of formula (IV) and the piperidine moiety or in the presence of standard peptide coupling agents.

It will be appreciated that under certain circumstances interconversions may interfere, for example, A or B hydroxy groups in A or B and the piperidine substituent  $\text{NH}_2$  will require protection e.g. as a carboxy- or silyl-ester group for hydroxy and as an acyl derivative for piperidine  $\text{NH}_2$ , during conversion of  $\text{R}^{1'}$ ,  $\text{R}^{2'}$ ,  $\text{R}^{3'}$  or  $\text{R}^{4'}$ , or during the coupling of the compounds of formulae (IV) and (V).

Compounds of formulae (IV) and (V) are known compounds, (see for example Smith *et al.*, *J. Amer. Chem. Soc.*, 1946, 68, 1301) or prepared analogously.

Compounds of formula (IV) where X is  $\text{CR}^6\text{R}^7\text{SO}_2\text{W}$  may be prepared by a route analogous to that of Ahmed El Hadri *et al.*, *J. Heterocyclic Chem.*, 1993, 30(3), 631. Thus compounds of formula (IV) where X is  $\text{CH}_2\text{SO}_2\text{OH}$  may be prepared by reacting the corresponding 4-methyl compound with N-bromosuccinimide, followed by treatment with sodium sulfite. The leaving group W may be converted to another leaving group W, e.g. a halogen group, by conventional methods.

The isocyanate of formula (IV) may be prepared conventionally from a 4-amino derivative such as 4-amino-quinoline, and phosgene, or phosgene equivalent (eg triphosgene) or it may be prepared more conveniently from a 4-carboxylic acid by a "one-pot" Curtius Reaction with diphenyl phosphoryl azide (DPPA) [see T. Shiori *et al.* *Chem. Pharm. Bull.* 35, 2698-2704 (1987)].

The 4-amino derivatives are commercially available or may be prepared by conventional procedures from a corresponding 4-chloro or 4-trifluoromethanesulphonate derivative by treatment with ammonia (O.G. Backeberg *et al.*, *J. Chem Soc.*, 381, 1942) or propylamine hydrochloride (R. Radinov *et al.*, *Synthesis*, 886, 1986).

4-Alkenyl compounds of formula (IV) may be prepared by conventional procedures from a corresponding 4-halogeno-derivative by e.g. a Heck synthesis as described in e.g. *Organic Reactions*, 1982, 27, 345.

4-Halogeno derivatives of compounds of formula (IV) are commercially available, or may be prepared by methods known to those skilled in the art. A 4-chloroquinoline is

prepared from the corresponding quinolin-4-one by reaction with phosphorus oxychloride ( $\text{POCl}_3$ ) or phosphorus pentachloride,  $\text{PCl}_5$ . A 4-chloroquinazoline is prepared from the corresponding quinazolin-4-one by reaction with phosphorus oxychloride ( $\text{POCl}_3$ ) or phosphorus pentachloride,  $\text{PCl}_5$ . A quinazolinone and quinazolines may be prepared by  
5 standard routes as described by T.A. Williamson in *Heterocyclic Compounds*, 6, 324 (1957) Ed. R.C. Elderfield.

4-Carboxy derivatives of compounds of formula (IV) are commercially available or may be prepared by conventional procedures for preparation of carboxy heteroaromatics well known to those skilled in the art. For example, quinazolines may be  
10 prepared by standard routes as described by T.A. Williamson in *Heterocyclic Compounds*, 6, 324 (1957) Ed. R.C. Elderfield. These 4-carboxy derivatives may be activated by conventional means, e.g. by conversion to an acyl halide or anhydride.

Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop  
15 and naphthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.

A 4-oxirane derivative of compounds of formula (IV) is conveniently prepared from the 4-carboxylic acid by first conversion to the acid chloride with oxalyl chloride and then reaction with trimethylsilyldiazomethane to give the diazoketone derivative.  
20 Subsequent reaction with 5M hydrochloric acid gives the chloromethylketone. Reduction with sodium borohydride in aqueous methanol gives the chlorohydrin which undergoes ring closure to afford the epoxide on treatment with base, e.g. potassium hydroxide in ethanol-tetrahydrofuran.

Alternatively and preferably, 4-oxirane derivatives can be prepared from  
25 bromomethyl ketones which can be obtained from 4-hydroxy compounds by other routes well known to those skilled in the art. For example, hydroxy compounds can be converted to the corresponding 4-trifluoromethanesulphonates by reaction with trifluoromethanesulphonic anhydride under standard conditions (see K. Ritter, *Synthesis*, 1993, 735). Conversion into the corresponding butyloxyvinyl ethers can be achieved by a  
30 Heck reaction with butyl vinyl ether under palladium catalysis according to the procedure of W. Cabri *et al*, *J. Org. Chem*, 1992, **57** (5), 1481. (Alternatively, the equivalent intermediates can be attained by Stille coupling of the trifluoromethanesulphonates or the analogous chloro derivatives with (1-ethoxyvinyl)tributyl tin, (T. R. Kelly, *J. Org. Chem.*, 1996, **61**, 4623).) The alkyloxyvinyl ethers are then converted into the  
35 corresponding bromomethylketones by treatment with N-bromosuccinimide in aqueous tetrahydrofuran in a similar manner to the procedures of J. F. W. Keana, *J. Org. Chem.*, 1983, **48**, 3621 and T. R. Kelly, *J. Org. Chem.*, 1996, **61**, 4623.

The 4-hydroxyderivatives can be prepared from an aminoaromatic by reaction with methylpropiolate and subsequent cyclisation, analogous to the method described in N. E. Heindel et al, *J. Het. Chem.*, 1969, 6, 77. For example, 5-amino-2-methoxy pyridine can be converted to 4-hydroxy-6-methoxy-[1,5]naphthyridine using this method.

5        If a chiral reducing agent such as (+) or (-)-B-chlorodiisopinocampheylborane ['DIP-chloride'] is substituted for sodium borohydride, the prochiral chloromethylketone is converted into the chiral chlorohydrin with ee values generally 85-95% [see C. Bolm et al, *Chem. Ber.* 125, 1169-1190, (1992)]. Recrystallisation of the chiral epoxide gives material in the mother liquor with enhanced optical purity (typically ee 95%).

10       The (*R*)-epoxide, when reacted with a piperidine derivative gives ethanolamine compounds as single diastereomers with (*R*)-stereochemistry at the benzylic position.

Alternatively, the epoxide may be prepared from the 4-carboxaldehyde by a Wittig approach using trimethylsulfonium iodide [see G.A. Epling and K-Y Lin, *J. Het. Chem.*, 1987, 24, 853-857], or by epoxidation of a 4-vinyl derivative.

15       4-Hydroxy-1,5-naphthyridines can be prepared from 3-aminopyridine derivatives by reaction with diethyl ethoxymethylene malonate to produce the 4-hydroxy-3-carboxylic acid ester derivative with subsequent hydrolysis to the acid, followed by thermal decarboxylation in quinoline (as for example described for 4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid, J. T. Adams et al., *J. Amer. Chem. Soc.*, 1946, 68,  
20       1317). A 4-hydroxy-[1,5]naphthyridine can be converted to the 4-chloro derivative by heating in phosphorus oxychloride, or to the 4-methanesulphonyloxy or 4-trifluoromethanesulphonyloxy derivative by reaction with methanesulphonyl chloride or trifluoromethanesulphonic anhydride, respectively, in the presence of an organic base. A 4-amino 1,5-naphthyridine can be obtained from the 4-chloro derivative by reaction with  
25       n-propylamine in pyridine.

Similarly, 6-methoxy-1,5-naphthyridine derivatives can be prepared from 3-amino-6-methoxypyridine.


1,5-Naphthyridines may be prepared by other methods well known to those skilled in the art (for examples see P.A. Lowe in "Comprehensive Heterocyclic Chemistry"  
30       Volume 2, p581-627, Ed A.R. Katritzky and C.W. Rees, Pergamon Press, Oxford, 1984).

The 4-hydroxy and 4-amino-cinnolines may be prepared following methods well known to those skilled in the art [see A.R. Osborn and K. Schofield, *J. Chem. Soc.* 2100 (1955)]. For example, a 2-aminoacetophenone is diazotised with sodium nitrite and acid to produce the 4-hydroxycinnoline with conversion to chloro and amino derivatives as  
35       described for 1,5-naphthyridines.


R<sup>A</sup> groups where the ring (y) is 4-pyridyl are available by the sequence described below, starting from an aromatic or heterocyclic amine (1), with at least one free CH



- position adjacent to the amine. Reaction with Meldrum's acid and trimethyl orthoformate in ethanol at reflux affords the corresponding 2,2-dimethyl-5-phenylaminomethylene-[1,3]dioxane-4,6-dione derivatives (2). These can be cyclised at elevated temperatures (180-220°C) in inert solvents such as Dowtherm to give the corresponding 1H-quinolin-4-one (3) or heterocyclic analogues eg 1H-[1,6]naphthyridin-4-one. These processes are well-established and are described by Walz and Sundberg (*J. Org. Chem.*, 2000, **65** (23), 8001) and by Todter and Lackner (*Synthesis*, 1997 (5) 576).




- Activation of the quinolone species related to (3) into the corresponding 4-quinolyl bromides (4) can be accomplished with phosphorous oxybromide or more preferably phosphorous tribromide in N,N-dimethylformamide (see M. Schmittel *et al*, *Synlett*, 1997, (9), 1096 and K. Gould *et al*, *J. Med., Chem.*, 1988, **31** (7), 1445). The corresponding chlorides (5) are available by using phosphoryl oxychloride (for instance C. W. Wright *et al*, *J. Med., Chem.*, 2001, **44** (19), 3187).




15

- Alternatively, the quinolone species may be activated to the corresponding 1,1,1-trifluoro-methanesulfonic acid quinolin-4-yl esters (6) by the action of agents such as triflic anhydride or more preferably N-trifluoromethanesulphonimide (see for example M. Alvarez *et al*, *Tet* 2000, **56** (23) 3703; M. Alvarez *et al*, *Eur. J. Org., Chem.*, 2000, (5), 849; J. Joule *et al*, *Tet*, 1998, **54** (17), 4405; J. K. Stille *et al*, *J.A.C.S.*, 1988, **110** (12), 4051).

- Activated species such as (4), (5), and (6) can then be subjected to a variety of metal-catalysed coupling reactions, such as amidation with primary carboxamides to give compounds such as (7) following the procedures of S. L. Buchwald *et al* (*J.A.C.S.*, 2001, **123**, 4051 and 7727; *Org. Lett.*, 1999, **1**, 35) or Sonogashira coupling with acetylenes to give compounds such as (8) (see A. Droz *et al*, *Helv. Chim. Acta.*, 2001, **84** (8), 2243; M. Belly *et al*, *Synlett*, 2001 (2), 222; M. Pirrung *et al*, *J.A.C.S.*, 2001, **123** (16), 3638).



(7)



(8)

$R^A$  thieno[3,2-b]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl, quinolin-8-yl and isoquinolin-5-yl derivatives are commercially available or prepared by conventional methods from commercially available or literature derivatives, for example  
 5 4H-thieno[3,2-b]pyridin-4-one, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (prepared by the method of H. Neunhoffer *et al*, Chem., Ber., 1990, 123), 2-methoxy-quinolin-8-ylamine (prepared by the method of K. Mislow *et al* J.A.C.S. 68, 1353 (1946)), 2,8-quinolinediol or trifluoromethane sulphonic acid-isoquinolin-5-yl ester (prepared as in D. Ortwine *et al*, J. Med. Chem., 1992, 35 (8), 1345).

10  $R^A$  quinoxalin-5-yl derivatives may be obtained from 2- or 3-methylquinoxalin-5-ol prepared as described by Y. Abe *et al*, J. Med. Chem., 1998, 41 (21), 4062 or from suitable substituted derivatives prepared by analogous methods.  $R^A$  3-methoxyquinoxaline-5-yl derivatives may be obtained from 3-oxoquinoxalin-5-yl prepared by the general methods of F.J. Wolf *et al*, J.A.C.S. 1949, 71, 6, using a suitable  
 15 methylating agent such as trimethylsilyl(diazomethane). The corresponding 1,2,3,4-tetrahydro-quinoxalin-5-yl may be prepared by reduction with a suitable reducing agent such as sodium cyanoborohydride in the presence of an acid such as acetic acid.

The isoquinolin-8-yl system can be prepared from the appropriately substituted benzylamine by cyclocondensation with diethoxy-acetaldehyde (see, for example, K.  
 20 Kido and Y. Watanabe, Chemical & Pharmaceutical Bulletin, 35(12), 4964-6; 1987). Alternatively 8-bromo-isoquinoline (prepared by the method of F.T. Tyson, J.A.C.S., 1939, 61, N. Briet *et al*, Tetrahedron (2002), 58(29), 5761-5766 or W.D. Brown, *et al*, Synthesis (2002), (1), 83-86. 183 can be subjected to N-oxidation and rearrangement to give 8-bromo-2H-isoquinolin-1-one. This can be N-methylated to give  
 25 8-bromo-2-methyl-2H-isoquinolin-1-one, an appropriate intermediate for the 2-methyl-1-oxo-1,2-dihydroisoquinolin-8-yl system.

The 1-methoxy-isoquinolin-8-yl system can also be obtained from the 8-bromoisoquinoline-N-oxide above by rearrangement with methyl chloroformate to give 8-bromo-1-methoxy-isoquinoline, an appropriate intermediate for the 1-methoxy-  
 30 isoquinolin-8-yl system.

For compounds of formula (V), suitable amines may be prepared from the corresponding 4-substituted piperidine acid or alcohol. In a first instance, an N-protected

piperidine containing an acid bearing substituent, can undergo a Curtius rearrangement and the intermediate isocyanate can be converted to a carbamate by reaction with an alcohol. Conversion to the amine may be achieved by standard methods well known to those skilled in the art used for amine protecting group removal. For example, an acid substituted N-protected piperidine can undergo a Curtius rearrangement e.g. on treatment with diphenylphosphoryl azide and heating, and the intermediate isocyanate reacts in the presence of 2-trimethylsilylethanol to give the trimethylsilylethylcarbamate (T.L. Capson & C.D. Poulter, *Tetrahedron Lett.*, 1984, 25, 3515). This undergoes cleavage on treatment with tetrabutylammonium fluoride to give the 4-amine substituted N-protected piperidine.

In a second instance, an N-protected piperidine containing an alcohol bearing substituent undergoes a Mitsunobu reaction (for example as reviewed in Mitsunobu, *Synthesis*, (1981), 1), for example with succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine. Removal of the phthaloyl group, for example by treatment with methylhydrazine, gives the amine of formula (V).

$R^5CH_2$ -halides, acyl derivative  $R^5COW$  and  $R^5SO_2W$  or aldehydes  $R^5CHO$  are commercially available or are prepared conventionally. The aldehydes may be prepared by partial reduction of the  $R^5$ -ester with lithium aluminium hydride or diisobutylaluminium hydride or more preferably by reduction to the alcohol, with lithium aluminium hydride or sodium borohydride or lithium triethylborohydride (see *Reductions by the Aluminio- and Borohydrides in Organic Synthesis*, 2nd ed., Wiley, N.Y., 1997; *JOC*, 3197, 1984; *Org. Synth. Coll.*, 102, 1990; 136, 1998; *JOC*, 4260, 1990; *TL*, 995, 1988; *JOC*, 1721, 1999; *Liebigs Ann./Recl.*, 2385, 1997; *JOC*, 5486, 1987), followed by oxidation to the aldehyde with manganese (II) dioxide, or by a 'Swern' procedure (oxalyl chloride/DMSO), or by using potassium dichromate (PDC). The aldehydes may also be prepared from carboxylic acids in two stages by conversion to a mixed carbonate for example by reaction with isobutyl chloroformate followed by reduction with sodium borohydride (R. J. Alabaster et al., *Synthesis*, 598, 1989) to give the hydroxymethyl substituted heteroaromatic or aromatic and then oxidation with a standard oxidising agent such as pyridinium dichromate or manganese (II) dioxide. Acyl derivative  $R^5COW$  may be prepared by activation of the  $R^5$ -ester.  $R^5CH_2$ -halides such as bromides may be prepared from the alcohol  $R^5CH_2OH$  by reaction with phosphorus tribromide in DCM/triethylamine.

Alternatively the aldehyde  $R^5CHO$  and sulphonic acid derivative  $R^5SO_2W$  may be generated by treatment of the  $R^5H$  heterocycle with suitable reagents. For example benzoxazinones, or more preferably their N-methylated derivatives can be formylated

with hexamine in either trifluoroacetic acid or methanesulfonic acid, in a modified Duff procedure [O. I. Petrov et al. *Collect. Czech. Chem. Commun.* **62**, 494-497 (1997)]. 4-Methyl-4H-benzo[1,4]oxazin-3-one may also be formylated using dichloromethyl methyl ether and aluminium chloride giving exclusively the 6-formyl derivative. Reaction of a R<sup>5</sup>H heterocycle with chlorosulphonic acid gives the sulphonic acid derivative (by methods analogous to Techer *et. al.*, *C.R.Hebd. Seances Acad. Sci. Ser. C*; **270**, 1601, 1970).

The aldehyde R<sup>5</sup>CHO may be generated by conversion of an R<sup>5</sup>halogen or R<sup>5</sup>trifluoromethane sulphonyloxy derivative into an olefin with subsequent oxidative cleavage by standard methods. For example, reaction of a bromo derivative under palladium catalysis with trans-2-phenylboronic acid under palladium catalysis affords a styrene derivative which upon ozonolysis affords the required R<sup>5</sup>CHO (Stephenson, G. R., *Adv. Asymmetric Synth.* (1996), 275-298. Publisher: Chapman & Hall, London).

R<sup>5</sup>H heterocycles are commercially available or may be prepared by conventional methods. For example where a benzoxazinone is required, a nitrophenol may be alkylated with for example ethyl bromoacetate and the resulting nitro ester reduced with Fe in acetic acid (alternatively Zn/AcOH/HCl or H<sub>2</sub>/Pd/C or H<sub>2</sub>/Raney Ni). The resulting amine may undergo spontaneous cyclisation to the required benzoxazinone, or cyclisation may be induced by heating in acetic acid. Alternatively a nitrophenol may be reduced to the aminophenol, which is reacted with chloroacetyl chloride [method of X. Huang and C. Chan, *Synthesis* 851 (1994)] or ethyl bromoacetate in DMSO [method of Z. Moussavi et al. *Eur. J. Med. Chim. Ther.* **24**, 55-60 (1989)]. The same general routes can be applied to prepare benzothiazinones [See for example F. Eiden and F. Meinel, *Arch. Pharm.* **312**, 302-312 (1979), H. Fenner and R. Grauert *Liebigs. Ann. Chem.* 193-313 (1978)]. A variety of routes are available to prepare aza analogues of benzothiazinones via the key corresponding aldehydes. For instance, 2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]thiazine-7-carbaldehyde may be accessed from 5-fluoro-2-picoline (E. J. Blanz, F. A. French, J. R. Do Amaral and D. A. French, *J. Med. Chem.* **1970**, *13*, 1124-1130) by constructing the thiazinone ring onto the pyridyl ring then functionalising the methyl substituent. The dioxin analogue of this aza substitution pattern, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde is accessible from Kojic acid by aminolysis from pyrone to pyridone then annelating the dioxin ring. Other aza substitution patterns with pyridothiazin-3-one, pyridooxazin-3-one, and pyridodioxin ring systems are also accessible. Ortho-aminothiophenols may be conveniently prepared and reacted as their zinc complexes [see for example V. Taneja et al *Chem. Ind.* 187 (1984)]. Benzoxazolones may be prepared from the corresponding aminophenol by reaction with carbonyl diimidazole, phosgene or triphosgene. Reaction of benzoxazolones with diphosphorus pentasulfide affords the

corresponding 2-thione. Thiazines and oxazines can be prepared by reduction of the corresponding thiazinone or oxazinone with a reducing agent such as lithium aluminium hydride.

5 The amines  $R^2R^4NH$  are available commercially or prepared conventionally. For example amines  $R^5CH_2NH_2$  may be prepared from a bromomethyl derivative by reaction with sodium azide in dimethylformamide (DMF), followed by hydrogenation of the azidomethyl derivative over palladium-carbon. An alternative method is to use potassium phthalimide/DMF to give the phthalimidomethyl derivative, followed by reaction with hydrazine in DCM to liberate the primary amine.

10 Conversions of  $R^{1a'}$ ,  $R^{1'}$ ,  $R^{2'}$ ,  $R^{3'}$  and  $R^{4'}$  may be carried out on the intermediates of formulae (IV), and (V) prior to their reaction to produce compounds of formula (I) in the same way as described above for conversions after their reaction.

Further details for the preparation of compounds of formula (I) are found in the examples.

15 The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds of formula (I). Libraries of compounds of formula (I) may be prepared by a combinatorial "split and mix" approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

20 Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I) or pharmaceutically acceptable derivatives thereof.

Novel intermediates of formulae (IV) and (V) are also part of this invention.

25 The antibacterial compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibacterials.

The pharmaceutical compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.

30 The composition may be formulated for administration by any route. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

35 The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

- 5           Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for  
10           example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid  
15           preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene  
20           glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

- For parenteral administration, fluid unit dosage forms are prepared utilizing the  
25           compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

- Advantageously, agents such as a local anaesthetic, preservative and buffering  
30           agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in  
35           the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before

suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

5 The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

10 No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable derivative thereof is administered in the above-mentioned dosage range.

The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibacterials. If the other  
15 antibacterial is a  $\beta$ -lactam then a  $\beta$ -lactamase inhibitor may also be employed.

Compounds of formula (I) are active against a wide range of organisms including both Gram-negative and Gram-positive organisms.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were  
20 specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.

25

Abbreviations in the examples:

RT = room temperature


ES = Electrospray mass spec.

LCMS = Liquid chromatography mass spec.

30 APCI+ = Atmospheric pressure chemical ionisation mass spec

**EXAMPLES**

**Example 1** 4-(2-{4-[(3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-ylmethyl)-amino]-piperidin-1-yl}-ethyl)-quinoline-6-carbonitrile dihydrochloride



- 5 (a) 4-[(2,2-Dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidenemethyl)-amino]-benzonitrile

A mixture of 4-amino-benzonitrile (12.5 g, 0.106 mol), 2,2-dimethyl-[1,3]dioxane-4,6-dione (18.3 g, 0.127 mol) and trimethylorthoformate (16 ml) in ethanol (100 ml) was refluxed for 3 hours. After cooling the solid was filtered off, washed with ethanol and air dried. The product was obtained as an off-white solid (27.9 g, 97%).

- 10 MS (+ve ion electrospray) m/z 273 (MH+).

- (b) 4-Oxo-1,4-dihydro-quinoline-6-carbonitrile

Intermediate (a) (27.5 g, 0.101 mol) was slowly added over five minutes to refluxing Dowtherm A (200 ml). After an additional five minutes at reflux, the mixture was allow to cool to room temperature then ether (200 ml) was added. The product was filtered off, thoroughly washed with ether then air dried to afford the product as a gold coloured solid (16.2 g, 94%).

- 15 MS (+ve ion electrospray) m/z 171 (MH+).

- 20 (c) 4-Bromo-quinoline-6-carbonitrile

To a solution of (b) (12 g, 70.5 mmol) in DMF (75 ml) was added dropwise phosphorous tribromide (8 ml, 84.6 mmol) over five minutes (slightly exothermic). The reaction was allowed to cool to room temperature and was then diluted with ice water (100 ml) and stirred 1 hour then diluted with additional water (300 ml). The product was

- 25 filtered off, washed with water and air dried to provide 14.3 g of product (87%).

MS (+ve ion electrospray) m/z 233 (MH+).

- (d) 4-Vinyl-quinoline-6-carbonitrile

To a solution of (c) (1 g, 4.3 mmol) and vinyltributyltin (1.5 mL, 5.17 mmol) in degassed toluene (20 ml) was added tetrakis(triphenylphosphine) palladium (0) (245 mg, 5 mol%) and the mixture was refluxed under argon for 2 hours. Evaporation and flash silica chromatography eluting with chloroform afforded the product as a pale yellow solid (500 mg, 64%).

- 30 MS (+ve ion electrospray) m/z 181 (MH+).

35



(e) {1-[2-(6-Cyano-quinolin-4-yl)-ethyl]-piperidin-4-yl}-carbamic acid *tert*-butyl ester

A mixture of (d) (150 mg, 0.8 mmol), piperidin-4-yl-carbamic acid *tert*-butyl ester (166 mg, 0.8 mmol) and chloroform (0.5 ml) were heated at 50°C in a loosely capped vial for 6 hours. The product was purified by flash silica chromatography eluting with a 0-2% methanol in chloroform gradient affording the product as a foam (304 mg, 96%).  
MS (+ve ion electrospray) m/z 381 (MH+).

(f) 2-Bromo-5-hydroxy-6-nitropyridine

3-Hydroxy-2-nitropyridine (20 g, 0.143 mole) was dissolved in methanol (400 ml) and a solution of 25% sodium methoxide in methanol (33 ml, 0.13 mol) was added at room temperature. The mixture was stirred for 30 minutes, then cooled to 0 °C, and bromine (7.2 ml, 0.14 mol) was added slowly. The reaction was then stirred at 0 °C for 30 minutes, then was quenched with glacial AcOH (2.5 ml). The solvent was removed *in vacuo* to afford material (30 g, 96%), which was used without further purification.  
MS (+ve ion electrospray) m/z 219 (MH+).

(g) Ethyl (6-bromo-2-nitro-pyridin-3-yloxy)acetate

The hydroxypyridine (f) (30 g, 0.14 mol) was suspended in acetone (200 ml), and potassium carbonate (39 g, 0.28 mol) was added, followed by ethyl bromoacetate (15.7 ml, 0.14 mmol). The reaction was heated at reflux for 10 hours, then was cooled to room temperature and diluted with Et<sub>2</sub>O. The precipitate was removed by suction filtration, and the filtrate was concentrated *in vacuo* to afford material (38 g, 89%), which was used without further purification.  
MS (+ve ion electrospray) m/z 305 (MH+).

(h) 6-Bromo-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

The nitropyridine (g) (38 g, 0.125 mol) was dissolved in glacial AcOH (150 ml), and iron powder (20 g, 0.36 mole) was added. The mixture was mechanically stirred and heated at 90°C for 5 hours, then was cooled to room temperature and diluted with EtOAc (300 ml). The mixture was filtered through a pad of silica gel and the filtrate was concentrated *in vacuo* and the residue recrystallized from MeOH (15 g, 52%).  
MS (+ve ion electrospray) m/z 229 (MH+).

(i) 6-((*E*)-Styryl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

The bromopyridine (h) (6.0 g, 26.3 mmol) and *trans*-2-phenylvinylboronic acid (3.9 g, 26.3 mmol) were dissolved in 1,4-dioxane (150 ml) and the solution was degassed with argon. (Ph<sub>3</sub>P)<sub>4</sub>Pd (230 mg, 0.2 mmol) was added, followed by a solution of

potassium carbonate (6.9 g, 50 mmol) in water (20 ml). The reaction was heated at reflux under argon overnight, then was cooled to room temperature and diluted with EtOAc (200 ml). The solution was washed sequentially with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated *in vacuo*. The solid residue was purified by flash chromatography on silica gel (5-10% EtOAc/CHCl<sub>3</sub>) to afford a solid (2.5g, 38%).  
5 MS (+ve ion electrospray) m/z 253 (MH<sup>+</sup>).



(j) 3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carboxaldehyde

The pyridine (i) (1.2 g, 4.8 mmol) was dissolved in dichloromethane (200 ml) and  
10 the solution was cooled to -78°C. Ozone was bubbled through the solution with stirring until a pale blue color appeared, then the excess ozone was removed by bubbling oxygen through the solution for 15 min. Dimethylsulfide (1.76 ml, 24 mmol) was added to the solution, and the reaction was stirred at -78 °C for 3 hours, then at room temperature overnight. The solvent was removed *in vacuo*, and the residue was triturated with Et<sub>2</sub>O  
15 (50 ml). The collected solid was washed with additional Et<sub>2</sub>O and dried to afford a solid (700 mg, 82%).  
MS (+ve ion electrospray) m/z 179 (MH<sup>+</sup>).

(k) Title compound:

20 A solution of (e) (119 mg, 0.31 mmol) in dichloromethane (2 ml) was treated with trifluoroacetic acid (2 ml) dropwise and then stirred at room temperature for 1 hour. Evaporation to dryness gave the crude trifluoroacetate salt of the amine which was redissolved in dichloromethane (3 ml) and methanol (1 ml). Aldehyde (j) (55 mg, 0.31 mmol) and triethylamine (0.17 ml) were added and the mixture was stirred at room  
25 temperature overnight. Sodium borohydride (38 mg, 1 mmol) was added and the reaction was allowed to stir for 1 hour. Dilution with chloroform, washing with saturated aqueous sodium bicarbonate, drying and evaporation gave an oil. Chromatography on silica gel eluting with 2-10% methanol in chloroform afforded the free base of the title compound as an oil. Redissolving in ethylacetate-methanol and treatment with 2 equivalents of HCl  
30 precipitated the dihydrochloride salt of the product which was filtered, washed with ether and dried (45 mg, 26%)  
<sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz): 8.92 (d, 1H), 8.48 (d, 1H), 8.20 (d, 1H), 7.84 (dd, 1H), 7.40 (d, 1H), 7.20 (d, 1H), 6.94 (d, 1H), 4.65 (s, 2H), 3.85 (s, 2H), 3.28 (m, 2H), 3.02 (m, 2H), 2.72 (m, 2H), 2.56 (m, 1H), 2.15 (m, 2H), 1.96 (m, 2H), 1.54 (m, 2H).  
35 MS (+ve ion electrospray) m/z 443 (MH<sup>+</sup>).

**Example 2** 6-((3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino)-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one dihydrochloride and 6-((3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino)-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one dihydrochloride



(a) 8-Benzyloxyquinolin-2-ol

To a stirred solution of 2,8-quinolinediol (30.84 mmol, 4.97 g; Fluka) and DBU (40.2 mmol, 6 mL) in isopropyl alcohol (60 mL) was added benzyl bromide (30.84 mmol, 3.7mL). The solution was heated at reflux overnight. The reaction mixture was allowed to cool and then concentrated *in vacuo*. The resulting residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 0.5 N NaOH, 10% HCl and water and dried over Na<sub>2</sub>SO<sub>4</sub>. Concentration provided 6 g (77%) of the tan solid, which was used without further purification. LC/MS: (ES) *m/z* 252 (M+H)<sup>+</sup>.

(b) 8-Benzyloxy-2-methoxyquinoline

8-Benzyloxyquinolin-2-ol (a) (6 g, 23.9 mmol) was added to POCl<sub>3</sub> (45 mL) and heated with stirring at 80 °C for 10 h. The reaction was allowed to cool to room temperature and the excess POCl<sub>3</sub> was decomposed by slowly pouring the mixture into water at 30 °C. The product was then extracted into toluene and the combined organic layers were washed with saturated aq. NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>. Concentration provided 6.9 g of a colorless oil, crude 2-chloro-8-benzyloxyquinoline, which was directly used in the next reaction step. LC/MS: (ES) *m/z* 270 (M+H)<sup>+</sup>.

The crude 2-chloro-8-benzyloxyquinoline from above was dissolved in toluene (10mL) and added to a stirred 25 wt% solution of NaOMe in MeOH (50 mL). The reaction solution was heated with stirring overnight at 70 °C. After cooling to room temperature, the reaction solution was poured onto ice and extracted with toluene. The

combined organic extracts were dried ( $\text{MgSO}_4$ ) and concentrated *in vacuo* to give a colorless oil (6.14 g, 92%). The product was used without further purification.

LC/MS: (ES)  $m/z$  266 ( $\text{M}+\text{H}$ )<sup>+</sup>.

5 (c) 1,1,1-Trifluoromethanesulfonic acid 2-methoxyquinolin-8-yl ester

8-Benzyloxy-2-methoxyquinoline (b) (6.14 g, 23 mmol) was dissolved in EtOH (50 mL) and treated with 10% Pd/C (600 mg). The reaction mixture was hydrogenated under an  $\text{H}_2$  atmosphere (20 psi) in a Parr shaker apparatus for 3.5 h. The reaction was filtered and concentrated to give 3.8 g (96%) of a colorless oil.

10 LC/MS: (ES)  $m/z$  176 ( $\text{M}+\text{H}$ )<sup>+</sup>.

The product from above (3.8 g, 22 mmol) was dissolved in DMF (40 mL) and treated with triethylamine (3.6 mL, 25.8 mmol) and N-

phenyltrifluoromethanesulfonimide (8.54 g, 23.9 mmol). The reaction mixture was heated with stirring at 40 °C for 8 h. Upon cooling to room temperature, aq.  $\text{K}_2\text{CO}_3$

15 solution was added and the product was extracted into  $\text{CH}_2\text{Cl}_2$ . The combined organic extracts were washed with water (5x75 mL), dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated to give 6.8 g (100%) of triflate as a light tan crystalline solid, which was used directly in the next reaction without additional purification. LC/MS: (ES)  $m/z$  308 ( $\text{M}+\text{H}$ )<sup>+</sup>.

20 (d) 2-Bromo-1-(2-methoxy-quinolin-8-yl)-ethanone

The triflate (2c) in DMF, triethylamine, butyl vinyl ether, palladium (II) acetate and 1,3-bis(diphenylphosphino)propane is heated at 60°C for 3 hours then evaporated and chromatographed on silica gel (dichloromethane).. The product is dissolved in THF and water and treated with N-bromosuccinimide for 1 hour, then evaporated and

25 chromatographed on silica gel to give the ketone.

(e) (R)-2-Bromo-1-(2-methoxy-quinolin-8-yl)-ethanol

The ketone (2d) in toluene is treated with (+)-B-chlorodiisopinocampheylborane ((+)-DIP-chloride) and stirred overnight, then diethanolamine is added and the mixture is

30 stirred for 3 hours, filtered and then evaporated. Chromatography on silica gel gives the product.

(f) 2-Methoxy-8-(R)-oxiranyl-quinoline

35 The alcohol (e) in methanol is stirred with potassium carbonate for 1 hour, then is evaporated and chromatographed on silica gel to give the product.

(g) (3R, 4S) and (3S, 4R)-4-Amino-1-*tert*-butoxycarbonyl-3-fluoropiperidine

To a solution of the enantiomeric mixture of *cis*-4-benzylamino-1-*tert*-butoxycarbonyl-3-fluoropiperidine (prepared according to the procedures of *J. Med. Chem.* 1999, 42, 2087-2104, 1.0 g, 3.2 mmole) in EtOH (40 mL) was added 3 N HCl (2.5 mL) and 10 % Pd/C (50 mg). The reaction was shaken under H<sub>2</sub> (40 psi) on a Parr  
5 apparatus for 14 h, then was filtered through Celite®. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (10% MeOH/CHCl<sub>3</sub>) to afford the title compound (370 mg, 53%) as a white solid. MS (ES) *m/e* 219 (M + H)<sup>+</sup>.

- 10 (h) (3R,4S) and (3S,4R)-4-Benzylloxycarbonylamino-3-fluoro-piperidine-1-carboxylic acid *tert*-butyl ester

The amine (2g) (5.49g) in dichloromethane (150 ml) containing triethylamine (3.5ml) was treated with benzyl chloroformate (4.0 ml) and stirred at room temperature for 5 hr. It was evaporated and chromatographed on silica gel to afford the product  
15 (4.27g).

- (i) ((3R,4S) and (3S,4R)-3-Fluoro-piperidin-4-yl)-carbamic acid benzyl ester

The carbamate (2h) (4.27g) was treated with trifluoroacetic acid (8 ml) in dichloromethane (40 ml) at room temperature for 3hr then evaporated to dryness. The  
20 residue was basified with sodium carbonate and extracted with 10% methanol-dichloromethane. The solution was dried (sodium sulfate) and evaporated to give the product as a white solid (2.92g).

- 25 (j) {(3R,4S) and (3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-yl}-carbamic acid benzyl ester

A 1:1 mixture of oxirane (2f) and piperidine (2i) is heated at 85°C for 3 hr and the product chromatographed on silica gel.

- 30 (k) (R)-2-((3R,4S) and (3S,4R)-4-Amino-3-fluoro-piperidin-1-yl)-1-(2-methoxy-quinolin-8-yl)-ethanol

The carbamate (2j) is hydrogenated in methanol at room temperature over 10% palladium charcoal, filtered and evaporated to afford the product.

- 35 (l) Methyl 3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxylate

A solution of ethyl 2-mercaptoacetate (1.473 ml) in DMF (48 ml) was ice-cooled and treated with sodium hydride (540 mg of a 60% dispersion in oil). After 1 hour methyl 6-amino-5-bromopyridine-2-carboxylate (3 g) (T.R. Kelly and F. Lang, *J. Org. Chem.* 61,

1996, 4623-4633) was added and the mixture stirred for 16 hours at room temperature. The solution was diluted with EtOAc (1 litre), washed with water (3 x 300ml), dried and evaporated to about 10 ml. The white solid was filtered off and washed with a little EtOAc to give the ester (0.95g).

5 MS (APCI-)  $m/z$  223 ([M-H]<sup>-</sup>, 100%)

(m) 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxylic acid

A solution of ester (2l) (788 mg) in dioxan (120 ml)/water (30 ml) was treated dropwise over 2 hours with 0.5M NaOH solution (8 ml) and stirred overnight. After  
10 evaporation to approx. 3 ml, water (5ml) was added and 2N HCl to pH4. The precipitated solid was filtered off, washed with a small volume of water and dried under vacuum to give a solid (636mg).

MS (APCI-)  $m/z$  209 ([M-H]<sup>-</sup>, 5%), 165([M-COOH]<sup>-</sup>, 100%)

15 (n) 6-Hydroxymethyl-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine

A solution of the carboxylic acid (2m) (500mg) in THF (24ml) with triethylamine (0.396ml) was cooled to -10°C and isobutyl chloroformate (0.339ml) added. After 20 minutes the suspension was filtered through kieselguhr into an ice-cooled solution of sodium borohydride (272 mg) in water (8 ml), the mixture stirred 30 minutes and the pH  
20 reduced to 7 with dilute HCl. The solvent was evaporated and the residue triturated under water. The product was filtered and dried under vacuum to give a white solid (346mg).  
MS (APCI-)  $m/z$  195 ([M-H]<sup>-</sup>, 50%), 165(100%)

(o) 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxaldehyde



25 A solution of the alcohol (2n) (330 mg) in dichloromethane (30 ml)/THF (30 ml) was treated with manganese dioxide (730 mg) and stirred at room temperature. Further manganese dioxide was added after 1 hour (730 mg) and 16 hours (300 mg). After a total of 20 hours the mixture was filtered through kieselguhr and the filtrate evaporated. The product was triturated with EtOAc/hexane (1:1) and collected to give a solid (180mg).  
30 MS (APCI-)  $m/z$  195 ([M-H]<sup>-</sup>, 95%), 165 (100%)

(p) Title compound

A mixture of the carboxaldehyde (2o) and amine (2k) (100 mg) in DMF/methanol/acetic acid with 3A molecular sieves is heated at 85°C for 2 hours, cooled  
35 and is treated with an excess of sodium cyanoborohydride. After stirring overnight, the mixture is diluted with chloroform (20 ml) and washed with aqueous Na<sub>2</sub>CO<sub>3</sub>. The organic fraction is dried and evaporated. Chromatography of the residue on silica gel

gives the free base of the title compound. Treatment with 4M HCl in dioxan, evaporation and trituration with ether affords the title compound

- Example 3** 6-((3R,4R)-3-Hydroxy-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino)-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one dihydrochloride and 6-((3S,4S)-3-Hydroxy-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino)-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one dihydrochloride



- 10 (a) *tert*-Butyl 3,6-dihydro-2*H*-pyridine-1-carboxylate  
1,2,3,6-tetrahydropyridine (15.0 g, 180 mmole) was added to a 10% aqueous solution of Na<sub>2</sub>CO<sub>3</sub> (50 mL) and the solution was cooled to 0 °C. Di-*tert*-butyl dicarbonate (39.8 g, 182 mmole) was added in portions over 15 min with vigorous stirring. The solution was stirred at 0 °C for 1 hr and then warmed to room temperature and stirred for an additional 18 hr. The reaction solution was partitioned between Et<sub>2</sub>O and saturated NaCl solution. The ether layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo* to give an oil (31.80 g, 96%), which needed no further purification. MS (ES) *m/z* 184 (M + H)<sup>+</sup>.
- 20 (b) *tert*-Butyl 7-oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylate  
A solution of (3a) (15.0 g, 81.9 mmole) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) was treated with a solution of meta-chloroperbenzoic acid (18.36 g, 106.4 mmole) in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) which was added over 30 minutes at 0 °C. The solution was allowed to warm to room temperature and stirred for 18 hr. The reaction solution was washed with 5% aqueous K<sub>2</sub>CO<sub>3</sub> and saturated NaCl solution, then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo* to yield an off-white solid. This was flash chromatographed on silica gel (20% EtOAc/hexanes) to yield a white solid (12.80 g, 78%). MS (ES) *m/z* 200 (M + H)<sup>+</sup>.

(c) *tert*-Butyl ( $\pm$ )-*trans*-4-benzylamino-3-hydroxypiperidine-1-carboxylate

The ester (3b) (13.24 g, 66.5 mmole) was combined with benzylamine (14.53 mL, 133 mmole) and stirred while heating at 115 °C. The reaction was allowed to stir for 8 hr at 115 °C and then allowed to cool to ambient temperature. EtOAc was added and the organic layer was washed sequentially with H<sub>2</sub>O and saturated NaCl solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to yield a yellow solid (19.31 g, 95%); LCMS:  $m/z$  307 (M + H)<sup>+</sup>. This mixture of regioisomers was chromatographed (preparative HPLC) on Lichrosphere silica gel 60A; 12  $\mu$ , 100 mm ID x 250 mm L; 70:30:0.5 hexanes:THF:diethylamine; 500 mL/min; uv detection 254 nm; 4.5 g mixture per injection. The products, *tert*-butyl ( $\pm$ )-*trans*-3-benzylamino-4-hydroxy-piperidine-1-carboxylate and *tert*-butyl ( $\pm$ )-*trans*-4-benzylamino-3-hydroxy-piperidine-1-carboxylate, as assigned by NMR, were obtained in a 3:1 ratio with retention times of 8.4 min and 6.5 min, respectively.

(d) *tert*-Butyl ( $\pm$ )-*trans*-4-amino-3-hydroxypiperidine-1-carboxylate

A solution of the ester (3c) (0.5 g, 1.63 mmole) in EtOH (40 mL) was treated with 10% palladium on carbon (catalytic) and hydrogenated in a Parr bottle for 6 hr at 40 psi. The solution was filtered through a plug of Celite®, and the filter pad was washed with EtOH. The filtrate was concentrated to yield a yellow oil (0.35 g, 99%). No further purification was required. MS (ES)  $m/z$  217 (M + H)<sup>+</sup>.

(e) *tert*-Butyl ( $\pm$ )-*trans*-3-Hydroxy-4-[3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)amino]piperidine-1-carboxylate

A solution of amine (3d) is heated at 85°C for 2 hours with the carboxaldehyde (2o) in DMF/methanol/acetic acid with 3A molecular sieves, cooled and is treated with an excess of sodium cyanoborohydride. After stirring overnight, the mixture is diluted with chloroform (20 ml) and washed with aqueous Na<sub>2</sub>CO<sub>3</sub>. The organic fraction is dried and evaporated. Chromatography of the residue on silica gel gives the product

(f) ( $\pm$ )-*trans*-3-Hydroxy-4-[3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)amino]piperidine


A solution of (3e) in CH<sub>2</sub>Cl<sub>2</sub> is treated with 4.0 N HCl/dioxane. The solution is allowed to stir for 30 min and then is concentrated *in vacuo* and dissolved in MeOH and treated with MP-Carbonate resin. The solution is then filtered and evaporated to dryness.

(g) Title compound



A 1:1 mixture of oxirane (2f) and piperidine (3f) is heated at 85°C for 3 hr and then chromatographed on silica gel to provide the product

**Example 4 6-((3R,4S)-1-[2-(2,3-Dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)-ethyl]-3-fluoro-piperidin-4-ylamino)-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one**



**(a) 7-Bromo-2,3-dihydro-benzo[1,4]dioxin-6-ylamine**

A solution of 2,3-dihydro-benzo[1,4]dioxin-6-ylamine (1 g, 6.6 mmol) in tetrahydrofuran (15 ml) was cooled to -78 deg C then treated with 1 drop of concentrated sulphuric acid followed by N-bromosuccinimide (1.2g, 6.6 mmol). The mixture was allowed to warm to room temperature over 1 hour then evaporated. The residue was dissolved in ether, washed with water then brine, dried and evaporated to afford an oil (1.4 g, 93%).

MS (+ve ion electrospray)  $m/z$  231 (MH<sup>+</sup>).

**(b) 5-[(7-Bromo-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione**

A mixture of aniline (4a) (14.8 g, 64.3 mmol), triethyl orthoformate (12.7 mL, 77.2 mmol) and 2,2-dimethyl-[1,3]dioxane-4,6-dione (Meldrum's acid) (11.1 g, 77.2 mmol) in ethanol (70 mL) was heated to reflux. After 1 hour the mixture was allowed to cool to room temperature then filtered, washing with ethanol then ether, to afford a white solid (22.9 g, 93%).

MS (+ve ion electrospray)  $m/z$  385 (MH<sup>+</sup>).

**(c) 6-Bromo-2,3-dihydro-7H-[1,4]dioxino[2,3-f]quinolin-10-one**

Enamine (4b) (22.9 g) was added portionwise to refluxing Dowtherm A (45 mL) over 3 minutes. After a further 3 minutes at reflux the mixture was cooled to room temperature. Ethyl acetate/hexane (10 mL/20 mL) was added and a black solid isolated by filtration. This residue was dissolved in hot methanol (400 mL) and filtered through Keiseluhr. Water (800 mL) was added and the mixture stored at 5°C overnight. Filtration and drying afforded a pale yellow solid (10.3 g, 61%).

MS (APCI<sup>-</sup>)  $m/z$  281 [M-H]<sup>-</sup>

**(d) 2,3-Dihydro-7H-[1,4]dioxino[2,3-f]quinolin-10-one**

- A suspension of (4c) (3.4 g, 12 mmol) in water/dioxan (150 mL/80 mL) was treated with 1M aqueous sodium hydroxide solution then hydrogenated over 10% palladium on charcoal (1.5 g) for 20 hours. The mixture was filtered then acidified with 5M aqueous hydrochloric acid. On concentrating to ca 100 mL, a solid began to crystallise out. The mixture was stored at 5°C overnight. Filtration and drying afforded a pale yellow solid (2.8 g, 100%).

MS (APCI<sup>-</sup>) *m/z* 202 [M-H]<sup>-</sup>

(e) 10-Bromo-2,3-dihydro-[1,4]dioxino[2,3-*f*]quinoline

- The quinolinone (4d) in dry DMF (8 mL) was cooled in ice and phosphorus tribromide (0.7 mL) added drop-wise, and the mixture was stirred, with ice-cooling for 30 minutes then allowed to warm to room temperature and stirred for a further 2 hours. It was cooled in ice and sodium carbonate solution was added and the solid was collected, washed well with water, and dried *in vacuo*, to afford a pale yellow solid (1.65 g).

- MS (ES) *m/z* 267 (M + H)<sup>+</sup>.

(f) 10-Vinyl-2,3-dihydro-[1,4]dioxino[2,3-*f*]quinoline

- To a solution of (4e) (0.8 g) and vinyltributyltin (1.05 mL) in degassed toluene (15 mL) was added tetrakis(triphenylphosphine) palladium (0) (173 mg) and the mixture was refluxed under argon for 2 days. More vinyltributyltin (0.8 mL) and tetrakis(triphenylphosphine) palladium (0) (173 mg) were added and the reaction mixture was heated at 130°C for a further 18 hours. Evaporation and flash silica chromatography eluting with hexane-DCM and ethyl acetate-DCM afforded the product as a yellow oil (500 mg, 64%).

- MS (+ve ion electrospray) *m/z* 214 (MH<sup>+</sup>).

(g) {(3R,4S)-1-[2-(2,3-Dihydro-[1,4]dioxino[2,3-*f*]quinolin-10-yl)-ethyl]-3-fluoro-piperidin-4-yl}-carbamic acid benzyl ester

- A mixture of (4f) (373 mg), piperidine (2i) (440 mg) and chloroform (3 mL) were heated at 120°C in a loosely capped vial for 18 hours, under argon. The product was purified by flash silica chromatography eluting with a 0-5% methanol in dichloromethane gradient affording the product as a foam (480 mg, 59%).

MS (+ve ion electrospray) *m/z* 466 (MH<sup>+</sup>).


- (h) (3R,4S)-1-[2-(2,3-Dihydro-[1,4]dioxino[2,3-*f*]quinolin-10-yl)-ethyl]-3-fluoro-piperidin-4-ylamine

The carbamate (4g) was hydrogenated in methanol at room temperature over 10% palladium charcoal, filtered and evaporated to afford the product (240mg, 71%)  
MS (+ve ion electrospray) m/z 332 (MH<sup>+</sup>).

5 (i) Title compound

- A mixture of aldehyde (2o) (142mg) and amine (4h) (240 mg) in DMF/methanol/acetic acid with 3A molecular sieves was heated at 85°C for 3 hours, cooled and was treated with an excess of sodium cyanoborohydride. After stirring overnight, the mixture was diluted with chloroform (20 ml) and washed with aqueous sodium bicarbonate. The organic fraction was dried and evaporated. Chromatography of the residue on silica gel gave the free base of the title compound (95mg).  
<sup>1</sup>H NMR δH (DMSO, 400MHz), 1.29-1.32 (2H, m), 1.66-1.68 (2H, d), 2.07 (2H, t), 2.56 (2H, m), 2.89 (2H, m), 3.20 (3H, m), 3.95 (3H, s), 6.76 (1H, d), 7.20 (1H, s), 7.35 (1H, d), 8.15 (1H, d), 8.72 (1H, s)  
 15 MS (+ve ion electrospray) m/z 510 (MH<sup>+</sup>).

**Example 5 6-[(1-[(2R/S)-2-hydroxy-2-[3-(methoxy)-5-quinoxaliny]ethyl]-4-piperidiny]amino]methyl]-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one dihydrochloride**



20 (a) 2-Nitro-6-triisopropylsilanyloxy-phenylamine

A solution of 2-amino-3-nitro-phenol (42.9g, 278 mmol) and imidazole (28.4g, 417 mmol) in tetrahydrofuran (750 ml) was treated with chloro-triisopropyl-silane (62.3g, 323 mmol). After 18 hours the mixture was filtered, diluted with ethyl acetate, washed with water, dried and evaporated to give an oil (91g).

25 MS (+ve ion electrospray) m/z 311 (MH<sup>+</sup>).

(b) 3-Triisopropylsilanyloxy-benzene-1,2-diamine

A solution of (5a) (91g) in ethanol (500 ml) was hydrogenated over 10% palladium on charcoal (8.5g) for 3 days then filtered and evaporated to give an oil (80.7g).

30 MS (+ve ion electrospray) m/z 281 (MH<sup>+</sup>).

(c) 8-Triisopropylsilanyloxy-1H-quinoxalin-2-one

A solution of (5b) (80.7g) in ethanol (1 litre) was treated with a 50% solution of ethyl glyoxalate in toluene (60 ml, 294 mmol) and heated to reflux for 2 hours. The

mixture was left at room temperature overnight and filtered affording 5-triisopropylsilanyloxy-1H-quinoxalin-2-one. The filtrate was evaporated and the residue chromatographed eluting with a 0-3% gradient of methanol in dichloromethane affording 8-triisopropylsilanyloxy-1H-quinoxalin-2-one as a white solid (14.9g).

5 MS (+ve ion electrospray) m/z 319 (MH+).

(d) 2-Methoxy-8-triisopropylsilanyloxy-quinoxaline

A solution of (5c) (2.0g, 6.2 mmol) in dichloromethane/methanol/acetonitrile (40 ml/4 ml/40 ml) was treated with triethylamine (1.1ml, 8 mmol) then a solution of  
10 (trimethylsilyl)diazomethane in hexane (2M; 4 ml, 8 mmol). The mixture was stirred overnight then evaporated. The residue was chromatographed on silica eluting with dichloromethane affording an oil (1.0g, 48%).

MS (+ve ion electrospray) m/z 333 (MH+).

15 (e) 3-Methoxy-quinoxalin-5-ol

A solution of (5d) (6.95g, 21 mmol) in tetrahydrofuran/methanol (280 ml/140 ml) was treated with caesium fluoride (4.73g, 31.4 mmol) and stirred for 18 hours. The mixture was evaporated and the residue partitioned between diethyl ether and dilute aqueous hydrochloric acid. The aqueous phase was further extracted with diethyl ether  
20 and the combined extracts dried and evaporated to give an oil (4.2g).

MS (+ve ion electrospray) m/z 177 (MH+).

(f) 1,1,1-Trifluoro-methanesulfonic acid 3-methoxy-quinoxalin-5-yl ester

A solution of (5e) (4.23g, 21 mmol) in dichloromethane (35 ml) was treated with  
25 triethylamine (4.5 ml, 32.1 mmol) then N-phenyltrifluoromethanesulfonimide (11.4g, 32 mmol) was added. The mixture was stirred overnight then washed with saturated aqueous sodium carbonate solution. The aqueous phase was further extracted with dichloromethane and the combined organic extracts were dried and evaporated. The residue was chromatographed on silica eluting with 50% hexane in dichloromethane and  
30 then dichloromethane, affording an oil (5.6g, 87%).

MS (+ve ion electrospray) m/z 309 (MH+).

(g) 1-(3-methoxyquinoxalin-5-yl)ethanone

To a solution of triflate (5f) (7.4g, 24.2 mmol) and 1,3- bis(diphenylphosphino)  
35 propane (1.0g, 0.24 mmol) in DMF (100mL), under argon, were added palladium acetate (0.55g, 0.24 mmol), triethylamine (6.73mL, 48.6 mmol) and butyl vinyl ether (12.6mL, 97.0 mmol). The reaction mixture was heated at 70°C for 8.5 hours. DMF was removed *in*

*vacuo* and the residue was chromatographed on a silica gel column eluting with 0-2% methanol in dichloromethane, affording the product as an oil (4.22g, 68%)  
MS (+ve ion electrospray) m/z 203 (MH+).

5 (h) 2,2-dibromo-1-[3-(methyloxy)-5-quinoxaliny]ethanone

To a solution of ethanone (5g) (3.95g, 19.5 mmol) in dioxan (40mL), a suspension of bromine (1.14mL, 22 mmol) in dioxan (40mL) was added at room temperature. The reaction mixture was stirred at room temperature over 2 nights. The reaction mixture was basified by addition of an aqueous solution of sodium bicarbonate and extracted several  
10 times with dichloromethane. The combined organic extracts were washed with an aqueous solution of sodium sulfite, dried over magnesium sulfate and evaporated in *vacuo*. The residue was chromatographed on a silica gel column eluting with 0-2% methanol in dichloromethane, affording the product as an oil (4.19g, 59%).  
MS (+ve ion electrospray) m/z 361 (MH+).

15

(i) 2-bromo-1-[3-(methyloxy)-5-quinoxaliny]ethanone

To a solution of ethanone (5h) (4.19g, 11.64 mmol) in THF (20mL), cooled to 0°C, a mixture of diethyl hydrogen phosphite (1.56mL, 12 mmol), and triethylamine (1.68mL, 12 mmol) in THF (10mL) was added slowly. The reaction mixture was allowed  
20 to reach room temperature overnight. More diethyl hydrogen phosphite (2x0.08mL), and triethylamine (2x0.08mL) were added and the reaction mixture was evaporated *in vacuo* after 7.5 hours. Water was added to the residue. A solid precipitated out, was washed with water and dried to afford the product as a white powder (2.68g, 82%).  
MS (+ve ion electrospray) m/z 282 (MH+).

25

(j) (+/-) 2-(methyloxy)-8-(2-oxirany)quinoxaline

The ketone (5i) (2.83g, 10.07mmol) was partially dissolved in methanol (50mL). The reaction mixture was cooled down to 0°C before sodium borohydride (0.78g, 20.6mmol) was added portionwise.. The reaction mixture was stirred at 0°C for 1 hour.  
30 More sodium borohydride was added (0.14g) and the new reaction mixture was stirred for a further 20 minutes. Cesium carbonate (7.5g, 20mmol) was then added and the reaction mixture was allowed to reach room temperature. Stirring at room temperature was continued for 3 days until total conversion to epoxide. The mixture was diluted with water and extracted several times with dichloromethane. The combined organic extracts  
35 were washed with water, dried over magnesium sulfate and evaporated in *vacuo*. The residue was chromatographed on a silica gel column eluting with 0-1% methanol in dichloromethane, affording the product as a white solid (0.83g, 41%)

MS (+ve ion electrospray) m/z 203 (MH<sup>+</sup>).

(k) (+/-) 1,1-dimethylethyl (1-{2-hydroxy-2-[3-(methyloxy)-5-quinoxaliny]ethyl}-4-piperidiny)carbamate

- 5           A mixture of oxirane (5j) (0.83g, 4.1mmol) and 1,1-dimethylethyl 4-piperidiny)carbamate (1.23g, 6.16mmol) in DMF (1mL) was heated at 90°C for 4 hours then cooled down to room temperature. The reaction mixture was diluted with ethyl acetate and washed with water. The aqueous layer was extracted a second time with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and  
10 evaporated *in vacuo*. The residue was chromatographed on a silica gel column eluting with 2-5% methanol in dichloromethane, affording the product as a white solid (1.46g, 88%)

MS (+ve ion electrospray) m/z 403 (MH<sup>+</sup>).

- 15 (l) (+/-) 2-(4-amino-1-piperidiny)-1-[3-(methyloxy)-5-quinoxaliny]ethanol

- A solution of amine (5k) in dioxan (10mL) was treated with 4.0N HCl/dioxan. The solution was allowed to stir at room temperature for 3.5 hours. The reaction mixture was diluted with diethyl ether and filtered. The precipitate was washed with more diethyl ether and dried *in vacuo*. It was then recrystallised from methanol/dichloromethane. The  
20 crystals were redissolved in a minimum amount of water and the solution was basified by addition of sodium bicarbonate. The solution was extracted several times with 10% methanol in dichloromethane. The combined organic extracts were dried over magnesium sulfate, filtered and evaporated *in vacuo* to afford the product as a solid (0.64g, 57%)  
MS (+ve ion electrospray) m/z 303 (MH<sup>+</sup>).

25

(m) Title compound


- A mixture of ethanol (5l) (30mg, 0.1mmol) and aldehyde (2o) (19mg, 0.1mmol) in chloroform/methanol with 3A molecular sieves was heated at reflux for 5 hours, cooled and was treated with sodium triacetoxyborohydride (42mg, 0.2mmol). After stirring for  
30 48 hours at room temperature, the mixture was diluted with chloroform and washed with aqueous sodium bicarbonate. The aqueous layer was extracted again with methanol/dichloromethane. The combined organic fractions were dried and evaporated. Chromatography of the residue on silica gel eluting with 5-10% methanol in dichloromethane gave the free base of the title compound (23mg, 48%).  
35 <sup>1</sup>H NMR δH (CDCl<sub>3</sub>, 250MHz), 1.60-1.91 (2H, m), 2.00-2.16 (2H, m) 2.15-2.20 (1H, m) 2.32-2.84 (6H, m), 3.47 (2H, s), 3.87 (2H, s), 4.05 (3H, s), 5.78 (1H, m), 6.98 (1H, d), 7.55-7.61 (2H, m), 7.91-7.94 (2H, m), 8.48 (1h, s)

MS (+ve ion electrospray)  $m/z$  481 (MH<sup>+</sup>).

Treatment with 4M HCl in dioxan, evaporation and trituration with ether afforded the title compound.

- The mixture of enantiomers was separated using Supercritical Fluid Chromatography (SFC) on Chiralpak AD stationary phase, eluting with 65% methanol (containing 0.5% isopropylamine) in liquid carbon dioxide. This provided the faster-running enantiomer (61 mg, Retention time = 9.4 minutes,  $\alpha_D = -91.5$  degrees) then the slower-running enantiomer (68 mg, Retention time = 19.9 minutes,  $\alpha_D = +89.1$  degrees).

**Example 6 (1R/S)-2-{4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-yl)methyl]amino}-1-piperidinyl}-1-[3-(methyloxy)-5-quinoxaliny]ethanol dihydrochloride**



**(a) 5-Benzoyloxy-2-hydroxymethyl-1 *H*-pyridin-4-one**

- A mixture of 5-benzoyloxy-2-hydroxymethyl-4-pyrone (prepared from Kojic acid by the method of D. Erol, J. Med. Chem., 1994, 29, 893) (9.7 g, 40 mmol), concentrated aqueous (880) ammonia (100 mL), and ethanol (20 mL) was heated to reflux overnight. The mixture was allowed to cool to room temperature then filtered. The resultant solid was washed with ether and dried in vacuo (5.9 g).

MS (APCI<sup>+</sup>)  $m/z$  232 (MH<sup>+</sup>).

**(b) (2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)-methanol**

- A solution of (6a) (2 g, 8.7 mmol) in water (220 mL) containing sodium hydroxide (17 mmol) was hydrogenated over 10% palladium on charcoal (1 g) for 4 hours. The mixture was filtered and evaporated to give a white solid. This solid was dissolved in N,N-dimethylformamide (8 mL) then treated with potassium carbonate (2.9 g) and 1,2-dibromoethane (0.6 mL, 7 mmol). The mixture was heated at 85°C overnight. The cooled mixture was evaporated onto silica and chromatographed eluting with 10-30% methanol in ethyl acetate affording a white solid (250 mg, 21 %).

MS (APCI<sup>+</sup>)  $m/z$  168 (MH<sup>+</sup>).

**(c) 2,3-Dihydro-[1,4]dioxino[2,3-c]pyridine-7-carboxaldehyde**


A solution of (6b) (250 mg, 1.5 mmol) in dichloromethane (5 mL) was treated with manganese dioxide (650 mg, 7.5 mmol). After 3 days the mixture was filtered and evaporated affording a white solid (150 mg, 61%).

MS (APCI+)  $m/z$  166 (MH+).

(d) Title compound

- The free base was prepared as in Example 5 from amine (5l) (30mg, 0.1mmol) and aldehyde (6c) (16mg, 0.1 mmol).  
<sup>1</sup>H NMR  $\delta$ H (CDCl<sub>3</sub>, 250MHz), 1.43-1.61 (2H, m), 1.90-1.95 (2H, m) 2.15 (1H, m) 2.37-2.94 (6H, m), 3.47 (2H, m), 3.81 (2H, s), 4.05 (3H, s), 4.25-4.35 (4H, m), 5.74-5.79 (1H, m), 6.83 (1H, d), 7.55-7.61 (1H, m), 7.91-7.94 (2H, m), 8.11 (1H, s), 8.48 (1H, s)  
 MS (+ve ion electrospray)  $m/z$  452 (MH+).  
 Treatment with 4M HCl in dioxan, evaporation and trituration with ether afforded the title compound.

**Example 7 {1-[2-(9-Chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)-ethyl]-piperidin-4-yl}-(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amine**



**dihydrochloride**

(a) 9-Chloro-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-10(7H)-one

- The quinolone (4d) (5.05g) in acetic acid (70mL) was sonicated and warmed until all had dissolved, and then it was treated with N-chlorosuccinimide (3.64g) and the mixture was heated at 35°C for 18 hr, cooled and the solid collected and washed with acetic acid and dried *in vacuo* at 40°C overnight, to give a white solid (1.65g)  
 MS (ES)  $m/z$  238/240 (M+H)<sup>+</sup>

(b) 10-Bromo-9-chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

- The chloroquinolone (7a) in dry DMF (8 mL) was cooled in ice and phosphorus tribromide (0.7 mL) added drop-wise, and the mixture was stirred, with ice-cooling for 30 minutes then allowed to warm to room temperature and stirred for a further 2 hours. It was cooled in ice and sodium carbonate solution was added and the solid was collected, washed well with water, and dried *in vacuo*, to afford a pale yellow solid (1.65 g).  
 MS (ES)  $m/z$  301/303 (M + H)<sup>+</sup>.

(c) 9-Chloro-10-vinyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline

The bromide (7b) (1.65 g) in DME (60 mL) under argon, was treated with tetrakis(triphenylphosphine)palladium(0) (0.32 g) and the mixture stirred at room temperature for 20 minutes. Anhydrous potassium carbonate (0.76 g), water (18 mL), and



vinylborane:pyridine complex (see F. Kerins and D O'Shea J. Org. Chem. 2002, 67, 4968-4971) was added and the mixture was heated at 100°C for 2 hr. It was cooled, diluted with water and extracted with ether, dried (magnesium sulfate) and evaporated to dryness. After work-up the product was chromatographed on silica gel, eluting with (methanol-DCM) to afford a white solid (1.35 g).  
MS (ES)  $m/z$  248/250 ( $M + H$ )<sup>+</sup>.

(d) {1-[2-(9-Chloro-2,3-dihydro-[1,4]dioxino[2,3-*f*]quinolin-10-yl)-ethyl]-piperidin-4-yl}-carbamic acid tert -butyl ester

- 10 A mixture of the vinyl-quinoline (7c) (680 mg) and piperidin-4-yl-carbamic acid tert-butyl ester (815 mg) in DMF (0.9 mL) and tetramethylguanidine (5 drops) was heated at 100°C for 18 hours. It was cooled, diluted with water and extracted with ethyl acetate, dried (magnesium sulfate) and evaporated to dryness. After work-up the product was chromatographed on silica gel, eluting with methanol-DCM to afford the desired product  
15 (0.82 g).  
MS (ES)  $m/z$  448 ( $M + H$ )<sup>+</sup>.

(e) 1-[2-(9-Chloro-2,3-dihydro-[1,4]dioxino[2,3-*f*]quinolin-10-yl)-ethyl]-piperidin-4-ylamine

- 20 The ester (7d) (0.82 g) in DCM (21 mL) was treated with TFA (21 mL) at room temperature for 1 hr and evaporated. Water and sodium carbonate were added and the solution was extracted with 10% methanol in ethyl acetate, dried (magnesium sulfate) and evaporated to afford the product (0.53g)  
MS (ES)  $m/z$  348 ( $M + H$ )<sup>+</sup>.

25

(f) Title compound


- The amine (7e) (0.53 g) and aldehyde (6c) (0.25 g) were dissolved in DMF (16 mL) and sodium triacetoxyborohydride (0.96 g) added and the solution was stirred overnight at room temperature. The reaction mixture was quenched with 2N HCl, basified with sodium bicarbonate solution, and extracted with methanol-DCM to afford the free base of the title compound (0.25g).

- <sup>1</sup>H NMR of the hydrochloride salt  $\delta$ H (d6-DMSO) 9.60 (2H, bs), 8.73 (1H, s), 8.20 (1H, s), 7.60 (1H, d), 7.45 (1H, d), 7.20 (1H, s), 4.50 (2H, m), 4.40 (4H, m), 4.32 (2H, m), 4.25 (2H, m), 3.90-3.70 (3H, m), 3.40-3.10 (6H, m), 2.35-2.05 (4H, m)  
35 MS (+ve ion electrospray)  $m/z$  497 (MH<sup>+</sup>).

This material, as a solution in chloroform/methanol, was treated with an excess of 1M HCl in ether and evaporated to dryness. The solid was triturated under ether, filtered and

dried under vacuum to provide the title compound (0.33g).

**Example 8 6-{{(1-{2-hydroxy-2-[2-(methoxy)-8-quinolinyl]ethyl}-4-piperidinyl)amino)methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one**



5

**(a) 8-(1-Butoxy-vinyl)-2-methoxy-quinoline**

Triflate (2c) (2.50 g, 8.14 mmol) was dissolved in DMF (25 mL). After subsequent addition of butyl vinyl ether (4.21 mL, 32.55 mmol), palladium acetate (0.182 g, 0.81 mmol), 1,3-bis(diphenylphosphino)propane (0.334 g, 0.81 mmol), and N,N-diisopropylethylamine (4.25 mL, 24.4 mmol), the reaction was heated to 60°C and stirred for 18 hours. The solution was then cooled to ambient temperature and poured into a saturated NaHCO<sub>3</sub> solution. The solution was then extracted with EtOAc and washed with water (3X). The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed under reduced pressure yielding an oil (2.80 g, >100% crude).<sup>1</sup>

15 MS (+ve ion electrospray) m/z 258 (MH<sup>+</sup>).

**(b) 2-Bromo-1-(2-methoxy-quinolin-8-yl)-ethanone**

Vinyl (8a) (2.42 g, 9.42 mmol) was dissolved in THF (30 mL). Water (10 mL) was added followed by N-bromosuccinimide (1.84 g, 10.36 mmol) at ambient temperature. Immediately after addition, the color changed to a lighter color. The reaction was stirred 10 minutes, filtered, and the solvent removed under reduced pressure. This was chromatographed on silica gel (CH<sub>2</sub>Cl<sub>2</sub>) to yield a yellow solid (1.25 g, 47%). MS (+ve ion electrospray) m/z 280 (MH<sup>+</sup>).

**25 (c) {1-[2-(2-Methoxy-quinolin-8-yl)-2-oxo-ethyl]-piperidin-4-yl}-carbamic acid tert-butyl ester.**

Piperidin-4-yl-carbamic acid tert-butyl ester (0.356 g, 1.78 mmol) was dissolved in dichloromethane (5.0 mL). Triethylamine (0.52 mL, 3.75 mmol) was added and the solution stirred for 15 minutes at ambient temperature. In a separate flask, bromomethyl (8b) (0.50 g, 1.78 mmol) was dissolved in dichloromethane (5.0 mL), and then added to the original solution. The reaction mixture was allowed to stir at ambient temperature for 18 hours. The solution was then diluted with ethyl acetate and washed with water and saturated aqueous NaCl solution. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered,

30

and the solvent removed under reduced pressure. The reaction yielded an off-white solid (0.501 g, 70%).

MS (+ve ion electrospray) m/z 400 (MH<sup>+</sup>).

- 5 (d) {1-[2-Hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-yl}-carbamic acid tert-butyl ester

The ketone (8c) (0.25 g, 0.627 mmol) was dissolved in tetrahydrofuran (10 mL) and the solution cooled to 0°C. NaBH<sub>4</sub> (0.024 g, 0.627 mmol) was added and the solution stirred at 0°C for 2 hours and allowed to warm to ambient temperature overnight. The  
10 reaction was not complete, and thus another equivalent of NaBH<sub>4</sub> (0.024 g, 0.627 mmol) was added at 0°C. The solution was allowed to warm to ambient temperature and was stirred for 3 more hours. The reaction was quenched with saturated NaHCO<sub>3</sub> solution and diluted with ethyl acetate. The organic layer was washed with water and saturated aqueous NaCl solution, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed under  
15 reduced pressure. Purification by flash chromatography (silica gel, acetone/chloroform) yielded an off-white solid (0.162 g, 65%).  
MS (+ve ion electrospray) m/z 402.4 (MH<sup>+</sup>).

- (e) (4-Amino-piperidin-1-yl)-1-(2-methoxy-quinolin-8-yl)-ethanol

20 The carbamate (8d) (0.158 g, 0.394 mmol) was dissolved in dichloromethane (2 mL). HCl in dioxane (1.0M: 5mL: 5 mmol) was added and the solution allowed to stir at room temperature for 18 hours. The solvent and excess HCl were removed under reduced pressure, yielding the di-HCl salt (0.144 g, 98%) as a yellow solid.  
MS (+ve ion electrospray) m/z 302.4 (MH<sup>+</sup>).

25

- (f) Title compound


Amine(8e) (0.144 g, 0.482 mmol) was added to aldehyde (1j) (0.094 g, 0.530 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and MeOH (3 mL). NaHCO<sub>3</sub> (0.202 g, 2.41 mmol) was then added and the solution allowed to stir at ambient temperature for 17 hours. The  
30 solution was cooled to 0°C, excess sodium borohydride was added, and it was allowed to stir at ambient temperature for 4 hours. The reaction mixture was poured into a saturated solution of NaHCO<sub>3</sub> and extracted with CHCl<sub>3</sub>. (3X). The organic layer was washed with water (2X) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to yield a yellow oil. This was chromatographed on silica gel (90:10:1 CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH) to yield an off-white  
35 solid (0.012 g, 5%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (d, 1H), 7.84 (d, 1H), 7.62 (d, 1H), 7.39 (t, 1H), 7.20 (d, 1H), 6.94 (d, 1H), 6.89 (d, 1H), 5.77 (dd, 1H), 4.63 (s, 3H), 4.02 (s, 3H), 3.84 (s, 2H),

3.15 (d, 1H), 3.01 (d, 1H), 2.59 (m, 2H), 2.38 (m, 1H), 2.21 (m, 1H); 1.97 (m, 2H); 1.58 (m, 2H).

MS (+ve ion electrospray) m/z 464.4 (MH<sup>+</sup>).

5 **Example 9 6-[(1-[2-(4-quinolinyl)ethyl]-4-piperidinyl)amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one dihydrochloride**



(a) 1,1-dimethylethyl {1-[2-(4-quinolinyl)ethyl]-4-piperidinyl} carbamate

A solution of lepidine (2.5 mmol, 0.33mL), 1,1-dimethylethyl 4-piperidinylcarbamate (2.5 mmol, 0.500g), 37% aqueous formaldehyde (2.6 mmol, 0.20mL), and 6N HCl (2.6 mmol, 0.44mL) in ethanol (1mL) was heated to 50°C overnight. The reaction mixture was cooled, diluted with chloroform, and washed with aqueous sodium bicarbonate solution. The aqueous layer was removed and the organic layer was washed with water and brine, dried over magnesium sulfate, filtered, concentrated and chromatographed in 90:10:1 chloroform:methanol:ammonium hydroxide to afford the product as a white solid (278mg, 31%).

15 LC-MS m/z 356 (MH<sup>+</sup>)

(b) 1-[2-(4-quinolinyl)ethyl]-4-piperidinamine trihydrochloride

20 1,1-dimethylethyl {1-[2-(4-quinolinyl)ethyl]-4-piperidinyl} carbamate (9a) (278mg) was dissolved in chloroform and diluted with 4N HCl in dioxane solution. After stirring two hours, the reaction mixture was evaporated to dryness to afford the product as a solid (180mg, 100%).

LC-MS m/z 286 (MH<sup>+</sup>)

(c) Title Compound


The trihydrochloride salt of amine (9b) (0.36 mmol, 180mg) was dissolved in 3mL of 1:1 dichloromethane:methanol and treated with sodium bicarbonate (1.8 mmol, 152mg) and carbaldehyde (2o) (0.36 mmol, 70mg) and stirred overnight. The suspension was treated with sodium triacetoxyborohydride (0.54 mmol, 114mg) and stirred overnight. The resulting reaction mixture was diluted with dichloromethane and poured into saturated aqueous sodium bicarbonate. The aqueous layer was extracted with

30

dichloromethane, and the combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered, concentrated, and chromatographed in 90:10:1 chloroform:methanol:ammonium hydroxide. The final product was obtained in 34% yield, 52mg and converted to dihydrochloride salt.

- 5  $\delta$ H (CDCl<sub>3</sub>, 400MHz), 8.81 (d, 1H), 8.11 (d, 1H), 8.09 (bs, 1H), 8.06(d, 1H), 7.70 (t, 1H), 7.63-7.55 (m, 2H), 7.28 (s, 1H), 6.99 (d, 1H), 3.85 (s, 2H), 3.43 (s, 2H), 3.28 (t, 2H), 3.04 (m, 2H), 2.73 (t, 2H), 2.56 (m, 1H), 2.17 (m, 1H), 1.95 (m, 1H), 1.64-1.52 (m, 2H)  
MS (ES) *m/e* 434 (M + H)<sup>+</sup>.

- 10 **Example 10 4-[2-(3-hydroxy-4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino}-1-piperidiny)ethyl]-6-quinolinecarbonitrile dihydrochloride (isomer E2)**



- (a) cis-4-tert-Butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester. Racemic cis-4-tert-butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester was prepared according to the procedure outlined by Kim et al. [Syn. Comm. 2001, 31, 1081-1089] starting from 3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester.  
MS (ES) *m/z* 351 (M + H)<sup>+</sup>.

- 20 (b) cis-4-tert-Butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester enantiomer 1 and cis-4-tert-Butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester enantiomer 2

- 71.0 g of the racemate (10a) was dissolved in methanol (710 mL) and resolved through multiple injections (1 x 8 g substrate injection; 5 x 10 g substrate injection; 1 x 7 g substrate injection; and 1 x 6 g substrate injection) on a Chiralpak AD column (77 x 250 mm) eluting with 100% methanol at a flow rate of 280 mL/minute with UV detection at 254 nm. 31.15 g of cis-4-tert-butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester fast running isomer (>99% ee, retention time 3.8 minutes (sharp), designated Isomer 1) and 26.75 g of cis-4-tert-butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester slow running isomer (>99% ee, retention time 8.0 minutes (very broad), designated Isomer 2) were obtained.

(c) cis-(3-Hydroxy-piperidin-4-yl)-carbamic acid tert-butyl ester isomer 2

10.0 g of cis-4-tert-Butoxycarbonylamino-3-hydroxy-piperidine-1-carboxylic acid benzyl ester slow running Isomer 2 (10b), was dissolved in methanol (350 mL) and was  
5 degassed. Pearlman's catalyst (palladium hydroxide on carbon, 20wt% Pd (dry basis),  $\leq$  50% water, 500 mg) was added and the mixture was purged with hydrogen and stirring continued under a balloon of hydrogen for 12 hours. The mixture was degassed with argon, filtered through a pad of Celite, and evaporated to dryness to afford 6.2 g (100%) of a white solid.

10 MS (ES)  $m/z$  217 ( $M + H$ )<sup>+</sup>.

(d) 1,1-dimethylethyl {(3*R*,4*S*)-1-[2-(6-cyano-4-quinolinyl)ethyl]-3-hydroxy-4-piperidinyl} carbamate

A mixture of the vinyl-quinoline (1d) and piperidine (10c) was treated as in  
15 example (7d) to afford the desired product in 86% yield.

MS (ES)  $m/z$  397 ( $M + H$ )<sup>+</sup>.

(e) 4-{2-[(3*R*,4*S*)-4-amino-3-hydroxy-1-piperidinyl]ethyl}-6-quinolinecarbonitrile dihydrochloride

20 The carbamate (10d) was dissolved in dichloromethane. 4M HCl in dioxane was added and the solution allowed to stir at room temperature for 18 hours. The solvent and excess HCl were removed under reduced pressure, yielding the di-HCl salt as a yellow solid.

MS (+ve ion electrospray)  $m/z$  297 ( $MH^+$ ).

25

(f) Title compound

The dihydrochloride salt (10e) (1.4 mmol, 650mg) was dissolved in 3mL methanol and diluted with 9mL dichloromethane. The solution was treated with triethylamine (7.1 mmol, 0.99mL) and aldehyde (1j) (1.4 mmol, 253mg) and stirred  
30 overnight. The resulting solution was treated with sodium borohydride (1.4 mmol, 54mg) and stirred two hours. The reaction mixture was diluted with chloroform and poured into saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with brine, dried over magnesium sulfate, filtered, concentrated, and chromatographed in 90:10:1  
35 chloroform:methanol:ammonium hydroxide to afford the product a solid (394mg, 60%).  
 $\delta$ H (DMSO, 400MHz), 8.94 (d, 1H), 8.81 (d, 1H), 8.15 (d, 1H), 8.05 (d, 1H), 7.58 (t, 1H), 7.30 (d, 1H), 7.02 (d, 1H), 4.61 (s, 2H), 4.43 (bs, 1H), 3.70 (m, 3H), 3.29 (t, 2H),


2.66 (t, 3H), 2.60 (bs, 1H), 2.39 (m, 1H), 2.28 (m, 1H), 2.00 (m, 1H), 1.66 (m, 1H), 1.52 (m, 1H)

MS (+ve ion electrospray) m/z 459 (MH<sup>+</sup>).

This material was converted to the dihydrochloride salt by the procedure of example (2p)

5

**Example 11** 4-[2-(3-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino)-1-piperidiny]ethyl]-6-quinolinecarbonitrile dihydrochloride (E2 isomer)



10 (a) Title compound

Dihydrochloride (10e) (1.4 mmol, 650mg) was dissolved in 3mL methanol and diluted with 9mL dichloromethane. The solution was treated with triethylamine (7.1 mmol, 0.99mL) and aldehyde (2o) (1.4 mmol, 345mg, at 80% purity) and stirred overnight. The resulting solution was treated with sodium borohydride (1.4 mmol, 54mg) and stirred two hours. The reaction mixture was diluted with chloroform and poured into saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted with chloroform, and the combined organic layers were washed with brine, dried over magnesium sulfate, filtered, concentrated, and chromatographed in 90:10:1 chloroform:methanol:ammonium hydroxide to afford the product as a solid (405mg, 60%).

20


$\delta$ H (DMSO, 400MHz), 10.91 (bs, 1H), 8.94 (d, 1H), 8.81 (d, 1H), 8.15 (d, 1H), 8.04 (d, 1H), 7.73 (d, 1H), 7.58 (d, 1H), 7.10 (d, 1H), 4.43 (bs, 1H), 3.72 (m, 3H), 3.53 (s, 1H), 3.28 (t, 2H), 3.17 (d, 1H), 2.66 (t, 1H), 2.60 (bs, 1H), 2.39 (m, 1H), 2.27 (m, 1H), 2.06 (m, 1H), 1.66 (m, 1H), 1.52 (m, 1H)

25

MS (+ve ion electrospray) m/z 475 (MH<sup>+</sup>).

This material was converted to the dihydrochloride salt by the procedure of example (2p)

**Example 12** 4-[2-(3-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino)-1-piperidiny]ethyl]-6-quinolinecarbonitrile(E1 isomer)




## (a) Title compound

Carbonitrile dihydrochloride (10e) (492 mg, 1.48 mmole), aldehyde (1j) (264 mg, 1.48 mmole) and triethylamine (1.03 mL, 7.42 mmole) were combined in a 1:1 mixture of dichloromethane and methanol (20 mL), and the mixture was stirred for 3 hours. Sodium borohydride (56 mg, 1.48 mmole) were added, and the reaction was stirred at room temperature for 30 minutes. The solution was diluted with chloroform, then washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to yield an off-white solid. This was flash chromatographed on silica gel (90:10:1 CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH) to yield the title compound (450 mg, 57%) as a white solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ 8.96 (d, 1 H), 8.79 (s, 1 H), 8.31 (s, 1 H), 8.17 (d, 1 H), 8.08 (d, 1 H), 7.70 (d, 1 H), 7.55 (s, 1 H), 7.01 (d, 1 H), 4.60 (s, 2 H), 4.45 (m, 1 H), 3.76-3.80 (m, 3 H), 3.24-3.37 (m, 2 H), 2.59-2.79 (m, 4 H), 2.40-2.50 (m, 1 H), 2.20-2.35 (m, 1 H), 1.65-1.78 (m, 1 H), 1.42-1.60 (m, 1 H), 1.00-1.13 (m, 2 H). MS (ES) m/e 459.5 (M + H)<sup>+</sup>.

This material was converted to the dihydrochloride salt by the procedure of example (2p)

**Example 13 4-[2-(3-hydroxy-4-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl]amino)-1-piperidiny]ethyl]-6-quinolinecarbonitrile(E1 isomer)**



## (a) Title compound

Carbonitrile dihydrochloride (10e) (492 mg, 1.48 mmole), aldehyde (2o) (287 mg, 1.48 mmole) and triethylamine (1.03 mL, 7.42 mmole) were combined in a 1:1 mixture of dichloromethane and methanol (20 mL), and the mixture was stirred for 3 hours. Sodium borohydride (56 mg, 1.48 mmole) were added, and the reaction was stirred at room temperature for 30 minutes. The reaction was diluted with chloroform, then washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to yield an off-white solid. This was flash



chromatographed on silica gel (90:10:1 CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH) to yield the title compound (230mg, 28%) as a white solid.

<sup>1</sup>H NMR (400 MHz, DMSO) δ 10.91 (s, 1 H), 8.95 (d, 1 H), 8.81 (s, 1 H), 8.32 (s, 1 H), 8.15 (d, 1 H), 8.04 (d, 1 H), 7.74 (d, 1 H), 7.59 (s, 1 H), 7.10 (d, 1 H), 4.45 (m, 1 H), 3.70-3.78 (s, 3 H), 3.51 (s, 2 H), 3.28-3.34 (m, 2 H), 2.66-2.79 (m, 4 H), 2.42-2.50 (m, 1 H), 2.25-2.35 (m, 1 H), 1.68-1.80 (m, 1 H), 1.43-1.60 (m, 1 H), 1.08-1.13 (m, 2 H)

MS (ES) m/e 475.5 (M + H)<sup>+</sup>.

This material was converted to the dihydrochloride salt by the procedure of example (2p)

10

### Biological Activity

The MIC (μg/ml) of test compounds against various organisms was determined including:

**S. epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis Ravasio, E. coli 7623.**

15

Examples 1, 5, 6, 7, 8, 11, 13 have an MIC ≤ 2 μg/ml versus all these organisms.


Examples 4, 10, 12 have an MIC ≤ 16 μg/ml versus all these organisms.

Example 9 has an MIC ≤ 16 μg/ml versus some of these organisms.

20

**Claims**


1. A compound of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

- 5 wherein:

$R^A$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system of structure:



- 10 containing 0-3 heteroatoms in each ring in which:  
 at least one of rings (x) and (y) is aromatic;  
 one of  $Z^4$  and  $Z^5$  is C or N and the other is C;  
 $Z^3$  is N,  $NR^{13}$ , O,  $S(O)_x$ , CO,  $CR^1$  or  $CR^1R^{1a}$ ;  
 $Z^1$  and  $Z^2$  are independently a 2 or 3 atom linker group each atom of which is  
 15 independently selected from N,  $NR^{13}$ , O,  $S(O)_x$ , CO,  $CR^1$  and  $CR^1R^{1a}$ ;  
 such that each ring is independently substituted with 0-3 groups  $R^1$  and/or  $R^{1a}$ ;  
 one of  $Z^1$ ,  $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$  is N, one is  $CR^{1a}$  and the remainder are CH, or one of  $Z^1$ ,  
 $Z^2$ ,  $Z^3$ ,  $Z^4$  and  $Z^5$  is  $CR^{1a}$  and the remainder are CH;  
 20  $R^1$  and  $R^{1a}$  are independently hydrogen; hydroxy;  $(C_{1-6})$ alkoxy optionally substituted by  
 $(C_{1-6})$ alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-  
substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups,  $CONH_2$ ,  
hydroxy,  $(C_{1-6})$ alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio,  
25 acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{1-6})$ alkoxy-substituted  $(C_{1-6})$ alkyl; hydroxy  $(C_{1-6})$   
alkyl; halogen;  $(C_{1-6})$ alkyl;  $(C_{1-6})$ alkylthio; trifluoromethyl; trifluoromethoxy; cyano;  
carboxy; nitro; azido; acyl; acyloxy; acylthio;  $(C_{1-6})$ alkylsulphonyl;  $(C_{1-6})$   
alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or  
amidino group optionally N-substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$   
30  $(C_{1-6})$ alkylsulphonyl groups, or when  $Z^3$  and the adjacent atom are  $CR^1$  and  $CR^{1a}$ ,  $R^1$  and  
 $R^{1a}$  may together represent  $(C_{1-2})$ alkylenedioxy;

provided that R<sup>1</sup> and R<sup>1a</sup>, on the same carbon atom are not both optionally substituted hydroxy or amino;

provided that

- 5 (i) when R<sup>A</sup> is optionally substituted quinolin-4-yl:
  - it is unsubstituted in the 6-position; or
  - it is substituted by at least one hydroxy (C<sub>1-6</sub>)alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position; or
  - it is substituted by at least one trifluoromethoxy group; or
- 10 R<sup>1</sup> and R<sup>1a</sup> together represent (C<sub>1-2</sub>)alkylenedioxy;
- (ii) when R<sup>A</sup> is optionally substituted quinazolin-4-yl, cinnolin-4-yl, 1,5-naphthyridin-4-yl, 1,7-naphthyridin-4-yl or 1,8-naphthyridin-4-yl:
  - it is substituted by at least one hydroxy (C<sub>1-6</sub>)alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position as available; or
  - 15 it is substituted by at least one trifluoromethoxy group; or
  - R<sup>1</sup> and R<sup>1a</sup> together represent (C<sub>1-2</sub>)alkylenedioxy;

R<sup>2</sup> is hydrogen, or (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl optionally substituted with 1 to 3 groups selected from:

- 20 amino optionally substituted by one or two (C<sub>1-4</sub>)alkyl groups; carboxy; (C<sub>1-4</sub>)alkoxycarbonyl; (C<sub>1-4</sub>)alkylcarbonyl; (C<sub>2-4</sub>)alkenyloxycarbonyl; (C<sub>2-4</sub>)alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-4</sub>)alkyl, hydroxy(C<sub>1-4</sub>)alkyl, aminocarbonyl(C<sub>1-4</sub>)alkyl, (C<sub>2-4</sub>)alkenyl, (C<sub>1-4</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-4</sub>)alkenylsulphonyl, (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl or (C<sub>2-4</sub>)alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R<sup>10</sup>; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R<sup>10</sup>; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C<sub>1-4</sub>)alkylthio; trifluoromethyl; hydroxy optionally substituted by (C<sub>1-4</sub>)alkyl, (C<sub>2-4</sub>)alkenyl, (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylcarbonyl, (C<sub>2-4</sub>)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl; oxo; (C<sub>1-4</sub>)alkylsulphonyl; (C<sub>2-4</sub>)alkenylsulphonyl; or (C<sub>1-4</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl;
- 30
- 35 R<sup>3</sup> is hydrogen; or
- R<sup>3</sup> is in the 2-, 3- or 4-position and is:


- trifluoromethyl; carboxy; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R<sup>10</sup>; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R<sup>10</sup>; or 5-oxo-1,2,4-oxadiazol-3-yl; or (C<sub>1-4</sub>)alkyl or ethenyl optionally substituted with any of the substituents listed above for R<sup>3</sup> and/or 0 to 2 groups R<sup>12</sup> independently selected from:
- halogen; (C<sub>1-6</sub>)alkylthio; trifluoromethyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; (C<sub>2-6</sub>)alkenylcarbonyl; hydroxy optionally substituted by (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylcarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl; amino optionally mono- or disubstituted by (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl, hydroxy(C<sub>1-6</sub>)alkyl, aminocarbonyl(C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; oxo; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>2-6</sub>)alkenylsulphonyl; or (C<sub>1-6</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; or
- R<sup>3</sup> is in the 2-position and is oxo; or
- R<sup>3</sup> is in the 3-position and is fluorine, amino optionally substituted by a group selected from hydroxy, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>1-6</sub>)alkyl and (C<sub>2-6</sub>)alkenyl, wherein a (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl moiety may be optionally substituted with up to 2 groups R<sup>12</sup>, or hydroxy optionally substituted as described above for R<sup>12</sup> hydroxy;

in addition when  $R^3$  is disubstituted with a hydroxy or amino containing substituent and carboxy containing substituent these may together form a cyclic ester or amide linkage, respectively;

$R^4$  is a group  $-U-R^5$  where

5  $U$  is selected from  $CO$ ,  $SO_2$  and  $CH_2$  and

$R^5$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



containing up to four heteroatoms in each ring in which

at least one of rings (a) and (b) is aromatic;

10  $X^1$  is C or N when part of an aromatic ring, or  $CR^{14}$  when part of a non-aromatic ring;

$X^2$  is N,  $NR^{13}$ , O,  $S(O)_x$ , CO or  $CR^{14}$  when part of an aromatic or non-aromatic ring or may in addition be  $CR^{14}R^{15}$  when part of a non aromatic ring;

$X^3$  and  $X^5$  are independently N or C;

15  $Y^1$  is a 0 to 4 atom linker group each atom of which is independently selected from N,  $NR^{13}$ , O,  $S(O)_x$ , CO and  $CR^{14}$  when part of an aromatic or non-aromatic ring or may additionally be  $CR^{14}R^{15}$  when part of a non aromatic ring;

$Y^2$  is a 2 to 6 atom linker group, each atom of  $Y^2$  being independently selected from N,  $NR^{13}$ , O,  $S(O)_x$ , CO,  $CR^{14}$  when part of an aromatic or non-aromatic ring or may additionally be  $CR^{14}R^{15}$  when part of a non aromatic ring;

20 each of  $R^{14}$  and  $R^{15}$  is independently selected from: H;  $(C_{1-4})$ alkylthio; halo; carboxy $(C_{1-4})$ alkyl; halo $(C_{1-4})$ alkoxy; halo $(C_{1-4})$ alkyl;  $(C_{1-4})$ alkyl;  $(C_{2-4})$ alkenyl;  $(C_{1-4})$ alkoxycarbonyl; formyl;  $(C_{1-4})$ alkylcarbonyl;  $(C_{2-4})$ alkenyloxycarbonyl;  $(C_{2-4})$ alkenylcarbonyl;  $(C_{1-4})$ alkylcarbonyloxy;  $(C_{1-4})$ alkoxycarbonyl $(C_{1-4})$ alkyl; hydroxy; hydroxy $(C_{1-4})$ alkyl; mercapto $(C_{1-4})$ alkyl;  $(C_{1-4})$ alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in  $R^3$ ;  $(C_{1-4})$ alkylsulphonyl;  $(C_{2-4})$ alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by  $(C_{1-4})$ alkyl or  $(C_{2-4})$ alkenyl; aryl; aryl $(C_{1-4})$ alkyl; aryl $(C_{1-4})$ alkoxy or

30  $R^{14}$  and  $R^{15}$  may together represent oxo;

each  $R^{13}$  is independently H; trifluoromethyl;  $(C_{1-4})$ alkyl optionally substituted by hydroxy,  $(C_{1-6})$ alkoxy,  $(C_{1-6})$ alkylthio, halo or trifluoromethyl;  $(C_{2-4})$ alkenyl; aryl; aryl  $(C_{1-4})$ alkyl; arylcarbonyl; heteroarylcarbonyl;  $(C_{1-4})$ alkoxycarbonyl;  $(C_{1-4})$ alkylcarbonyl; formyl;  $(C_{1-6})$ alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by  $(C_{1-4})$ alkoxycarbonyl,  $(C_{1-4})$ alkylcarbonyl,  $(C_{2-4})$

4)alkenyloxycarbonyl, (C<sub>2-4</sub>)alkenylcarbonyl, (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl and optionally further substituted by (C<sub>1-4</sub>)alkyl or (C<sub>2-4</sub>)alkenyl;

each x is independently 0, 1 or 2

5

n is 0 and AB is NR<sup>11</sup>CO, CO-CR<sup>8</sup>R<sup>9</sup>, CR<sup>6</sup>R<sup>7</sup>-CO, NHR<sup>11</sup>SO<sub>2</sub>, CR<sup>6</sup>R<sup>7</sup>-SO<sub>2</sub> or CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>, provided that R<sup>8</sup> and R<sup>9</sup> are not optionally substituted hydroxy or amino and R<sup>6</sup> and R<sup>8</sup> do not represent a bond:

or n is 1 and AB is NR<sup>11</sup>CO, CO-CR<sup>8</sup>R<sup>9</sup>, CR<sup>6</sup>R<sup>7</sup>-CO, NR<sup>11</sup>SO<sub>2</sub>, CONR<sup>11</sup>, CR<sup>6</sup>R<sup>7</sup>-CR<sup>8</sup>R<sup>9</sup>, O-CR<sup>8</sup>R<sup>9</sup> or NR<sup>11</sup>-CR<sup>8</sup>R<sup>9</sup>;

10

provided that R<sup>6</sup> and R<sup>7</sup>, and R<sup>8</sup> and R<sup>9</sup> are not both optionally substituted hydroxy or amino;

and wherein:

15 each of R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> is independently selected from: H; (C<sub>1-6</sub>)alkoxy; (C<sub>1-6</sub>)alkylthio; halo; trifluoromethyl; azido; (C<sub>1-6</sub>)alkyl; (C<sub>2-6</sub>)alkenyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; (C<sub>2-6</sub>)alkenyloxycarbonyl; (C<sub>2-6</sub>)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R<sup>3</sup>; (C<sub>1-6</sub>)alkylsulphonyl; (C<sub>2-6</sub>)alkenylsulphonyl; or (C<sub>1-6</sub>)aminosulphonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl;

20

or R<sup>6</sup> and R<sup>8</sup> together represent a bond and R<sup>7</sup> and R<sup>9</sup> are as above defined;

R<sup>10</sup> is selected from (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl and aryl any of which may be optionally substituted by a group R<sup>12</sup> as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkenyl, (C<sub>1-6</sub>)alkylsulphonyl, trifluoromethylsulphonyl, (C<sub>2-6</sub>)alkenylsulphonyl, (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl or (C<sub>2-6</sub>)alkenylcarbonyl and optionally further substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl; and

30

R<sup>11</sup> is hydrogen; trifluoromethyl, (C<sub>1-6</sub>)alkyl; (C<sub>2-6</sub>)alkenyl; (C<sub>1-6</sub>)alkoxycarbonyl; (C<sub>1-6</sub>)alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C<sub>1-6</sub>)alkoxycarbonyl, (C<sub>1-6</sub>)alkylcarbonyl, (C<sub>2-6</sub>)alkenyloxycarbonyl, (C<sub>2-6</sub>)alkenylcarbonyl, (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl and optionally further substituted by (C<sub>1-6</sub>)alkyl or (C<sub>2-6</sub>)alkenyl;

35

or where one of R<sup>3</sup> and R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> or R<sup>9</sup> contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage.



2. A compound according to claim 1 wherein R<sup>A</sup> is optionally substituted  
 5 isoquinolin-5-yl, quinolin-8-yl, thieno[3,2-b]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl, quinoxalin-5-yl, isoquinolin-8-yl, [1,6]-naphthyridin-4-yl, 1,2,3,4-tetrahydroquinoxalin-5-yl or 1,2-dihydroisoquinoline-8-yl..
3. A compound according to any preceding claim wherein R<sup>1</sup> is H, methoxy, methyl,  
 10 cyano or halogen and R<sup>1a</sup> is H.
4. A compound according to any preceding claim wherein R<sup>3</sup> is hydrogen; optionally substituted hydroxy; optionally substituted amino; halogen; (C<sub>1-4</sub>)alkoxycarbonyl; CONH<sub>2</sub>; 1-hydroxyalkyl; CH<sub>2</sub>CO<sub>2</sub>H; CH<sub>2</sub>CONH<sub>2</sub>; -CONHCH<sub>2</sub>CONH<sub>2</sub>; 1,2-  
 15 dihydroxyalkyl; CH<sub>2</sub>CN; 2-oxo-oxazolidin-5-yl; or 2-oxo-oxazolidin-5-yl(C<sub>1-4</sub>alkyl).
5. A compound according to any preceding claim wherein n is 0 and A and B are both CH<sub>2</sub>, A is CHOH and B is CH<sub>2</sub> or A is NH and B is CO.
- 20 6. A compound according to any preceding claim wherein -U- is -CH<sub>2</sub>-.
7. A compound according to any preceding claim wherein the heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR<sup>13</sup> in which Y<sup>2</sup> contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded  
 25 to X<sup>3</sup> or the heterocyclic ring (A) has ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non aromatic and Y<sup>2</sup> has 3-5 atoms, including a heteroatom bonded to X<sup>5</sup> selected from O, S or NR<sup>13</sup>, where R<sup>13</sup> is other than hydrogen, and NHCO bonded via N to X<sup>3</sup>, or O bonded to X<sup>3</sup>.
- 30 8. A compound according to any one of claims 1 to 6 wherein R<sup>5</sup> is selected from:  
 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl  
 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl  
 7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl  
 7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl  
 35 2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl.
9. A compound according to claim 1 selected from:

- 4-(2-{4-[(3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-ylmethyl)-amino]-piperidin-1-yl}-ethyl)-quinoline-6-carbonitrile 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
- 5 6-({(3S,4R)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
- 6-({(3R,4R)-3-Hydroxy-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
- 6-({(3S,4S)-3-Hydroxy-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
- 10 6-({(3R,4S)-1-[2-(2,3-Dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)-ethyl]-3-fluoro-piperidin-4-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
- 6-{{(1-[(2R/S)-2-hydroxy-2-[3-(methyloxy)-5-quinoxaliny]ethyl]-4-piperidinyl)amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one
- 15 (1R/S)-2-{4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}-1-[3-(methyloxy)-5-quinoxaliny]ethanol
- {1-[2-(9-Chloro-2,3-dihydro-[1,4]dioxino[2,3-f]quinolin-10-yl)-ethyl]-piperidin-4-yl}-2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-amine 6-{{(1-{2-hydroxy-2-[2-(methyloxy)-8-quinoliny]ethyl}-4-piperidinyl)amino}methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 20 6-{{(1-[2-(4-quinoliny]ethyl)-4-piperidinyl)amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one
- 4-[2-(3-hydroxy-4-{{(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl}amino}-1-piperidinyl)ethyl]-6-quinolinecarbonitrile (isomer E2)
- 25 4-[2-(3-hydroxy-4-{{(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl}amino}-1-piperidinyl)ethyl]-6-quinolinecarbonitrile (isomer E2)
- 4-[2-(3-hydroxy-4-{{(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl}amino}-1-piperidinyl)ethyl]-6-quinolinecarbonitrile(E1 isomer)
- 4-[2-(3-hydroxy-4-{{(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)methyl}amino}-1-piperidinyl)ethyl]-6-quinolinecarbonitrile(E1 isomer)
- 30 or a pharmaceutically acceptable derivative thereof.

10. A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound according to claim 1.
- 35




11. The use of a compound according to claim 1, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
12. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier for use in the treatment of bacterial infections in mammals.
13. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.
14. A compound according to claim 1 for use as a medicament.
15. A compound according to claim 1 for use in the treatment of bacterial infections in mammals.
16. A process for preparing a compound of formula (I) according to claim 1, or a pharmaceutically acceptable derivative thereof, which process comprises reacting a compound of formula (IV) with a compound of formula (V):



- wherein n is as defined in formula (I); Z<sup>1'</sup>, Z<sup>2'</sup>, Z<sup>3'</sup>, R<sup>1'</sup>, and R<sup>3'</sup> are Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>3</sup>, R<sup>1</sup>, and R<sup>3</sup> as defined in formula (I) or groups convertible thereto; Z<sup>4</sup> and Z<sup>5</sup> are as defined in formula (I);
- Q<sup>1</sup> is NR<sup>2'</sup>R<sup>4'</sup> or a group convertible thereto wherein R<sup>2'</sup> and R<sup>4'</sup> are R<sup>2</sup> and R<sup>4</sup> as defined in formula (I) or groups convertible thereto and Q<sup>2</sup> is H or R<sup>3'</sup> or Q<sup>1</sup> and Q<sup>2</sup> together form an optionally protected oxo group;
- (i) X is A'-COW, Y is H and n is 0;
- (ii) X is CR<sup>6</sup>=CR<sup>8</sup>R<sup>9</sup>, Y is H and n is 0;
- (iii) X is oxirane, Y is H and n is 0;
- (iv) X is N=C=O and Y is H and n is 0;
- (v) one of X and Y is CO<sub>2</sub>R<sup>y</sup> and the other is CH<sub>2</sub>CO<sub>2</sub>R<sup>x</sup>;
- (vi) X is CHR<sup>6</sup>R<sup>7</sup> and Y is C(=O)R<sup>9</sup>;
- (vii) X is CR<sup>7</sup>=PR<sup>z</sup><sub>3</sub> and Y is C(=O)R<sup>9</sup> and n=1;
- (viii) X is C(=O)R<sup>7</sup> and Y is CR<sup>9</sup>=PR<sup>z</sup><sub>3</sub> and n=1;

- (ix) Y is COW and X is  $\text{NHR}^{11'}$ , NCO or  $\text{NR}^{11'}\text{COW}$  and  $n=0$  or 1 or when  $n=1$  X is COW and Y is  $\text{NHR}^{11'}$ , NCO or  $\text{NR}^{11'}\text{COW}$ ;
- (x) X is  $\text{NHR}^{11'}$  and Y is  $\text{C}(=\text{O})\text{R}^8$  and  $n=1$ ;
- (xi) X is  $\text{NHR}^{11'}$  and Y is  $\text{CR}^8\text{R}^9\text{W}$  and  $n=1$ ;
- 5 (xii) X is  $\text{NR}^{11'}\text{COCH}_2\text{W}$  or  $\text{NR}^{11'}\text{SO}_2\text{CH}_2\text{W}$  and Y is H and  $n=0$ ;
- (xiii) X is  $\text{CR}^6\text{R}^7\text{SO}_2\text{W}$  and Y is H and  $n=0$ ;
- (xiv) X is W or OH and Y is  $\text{CH}_2\text{OH}$  and  $n$  is 1;
- (xv) X is  $\text{NHR}^{11'}$  and Y is  $\text{SO}_2\text{W}$  or X is  $\text{NR}^{11'}\text{SO}_2\text{W}$  and Y is H, and  $n$  is 0;
- (xvi) X is W and Y is  $\text{CONHR}^{11'}$ ;
- 10 (xvii) X is  $-\text{CH}=\text{CH}_2$  and Y is H and  $n=0$ ;
- in which W is a leaving group, e.g. halo, methanesulphonyloxy, trifluoromethanesulphonyloxy or imidazolyl;  $\text{R}^x$  and  $\text{R}^y$  are  $(\text{C}_{1-6})\text{alkyl}$ ;  $\text{R}^z$  is aryl or  $(\text{C}_{1-6})\text{alkyl}$ ;  $\text{A}'$  and  $\text{NR}^{11'}$  are A and  $\text{NR}^{11}$  as defined in formula (I), or groups convertible thereto; and oxirane is:

15



wherein  $\text{R}^6$ ,  $\text{R}^8$  and  $\text{R}^9$  are as defined in formula (I);

and thereafter optionally or as necessary converting  $\text{Q}^1$  and  $\text{Q}^2$  to  $\text{NR}^{2'}\text{R}^{4'}$ ; converting  $\text{A}'$ ,  $\text{Z}^1$ ,  $\text{Z}^2$ ,  $\text{Z}^3$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{NR}^{11'}$  to A,  $\text{Z}^1$ ,  $\text{Z}^2$ ,  $\text{Z}^3$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$  and  $\text{NR}^{11}$ ;

- 20 converting A-B to other A-B, interconverting  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$  and/or  $\text{R}^4$ , and/or forming a pharmaceutically acceptable derivative thereof.

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number  
**WO 2004/002490 A3**

(51) International Patent Classification?: **A61K 31/535**,  
31/54, A61P 31/04, C07D 498/04, 491/04, 513/04, 519/00

(21) International Application Number:  
PCT/EP2003/006754

(22) International Filing Date: 25 June 2003 (25.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/391,710 26 June 2002 (26.06.2002) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AXTEN, Jeffrey, Michael** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **DAINES, Robert, A.** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **DAVIES, David, Thomas** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **GALLAGHER, Timothy, Francis** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US). **JONES, Graham, Elgin** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **MILLER, William, Henry** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089,

Collegeville, PA 19426-0989 (US). **PEARSON, Neil, David** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **PENDRAK, Israil** [US/US]; GlaxoSmithKline, 1250S. Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US).

(74) Agent: **VALENTINE, Jill, Barbara**; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).




Published:

— with international search report

(88) Date of publication of the international search report:  
27 October 2005

[Continued on next page]

(54) Title: PIPERIDINE COMPOUNDS AS ANTIBACTERIALS



(57) Abstract: Piperidine derivatives and pharmaceutically acceptable derivatives of formula (I) thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. Wherein:  $R^A$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system of structure (i), and  $R^4$  is a group  $-U-R^5$  where U is selected from CO,  $SO_2$  and  $CH_2$  and  $R^5$  is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A).



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06754

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/535 A61K31/54 A61P31/04 C07D498/04 C07D491/04  
C07D513/04 C07D519/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/08224 A (DAVIES DAVID THOMAS ;MARKWELL ROGER EDWARD (GB); JONES GRAHAM ELGI) 31 January 2002 (2002-01-31) claims, examples -----	1-16
P,A	WO 02/056882 A (DAVIES DAVID THOMAS ;MARKWELL ROGER EDWARD (GB); JONES GRAHAM ELGI) 25 July 2002 (2002-07-25) claims, examples -----	1-16
E	WO 03/064421 A (GLAXO GROUP LTD ;PEARSON NEIL DAVID (GB); SEEFELD MARK ANDREW (US)) 7 August 2003 (2003-08-07) claims, examples ----- -/--	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

8 August 2005

Date of mailing of the international search report

12 08. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stroeter, T

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06754

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03/064431 A (GLAXO GROUP LTD.; PEARSON-NEIL DAVID (GB); SEEFELD MARK ANDREW (US)) 7 August 2003 (2003-08-07) claims, examples	1-16
X	US 6 323 217 B2 (POITEVIN CHRISTOPHE ET AL) 27 November 2001 (2001-11-27) claims, examples 5,21,23,41,44,86	1-16
X	EP 0 445 862 A (JANSSEN PHARMACEUTICA NV) 11 September 1991 (1991-09-11) examples of tables 2 and 3, e.g. co.no.45 on page 30.claims 1-4	1-16
X	GB 1 375 836 A (JOHN WYETH & BROTHER LTD.) 27 November 1974 (1974-11-27) formula (I) with substructure (IIc) example 13	1-16
X	US 5 610 157 A (VAN DAELE GEORGES H P ET AL) 11 March 1997 (1997-03-11) claims, tables 2,3	1-16

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/06754

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet.

As a result of the prior review under R. 40.2(e) PCT  
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
1-7, 10-16(each partial), 8 and 9 (each complete)
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 3-8, 10-16 (each partial)

compounds (and subject-matter referring to these compounds)  
of formula (I) wherein RA is a carbocyclic bicyclic system.  
---

2. claims: 1-6, 10-16 (each partial)

compounds (and subject-matter referring to these compounds)  
of formula (I) wherein RA is a heterocyclic bicyclic system  
and R5 is a carbocyclic bicyclic system.  
---

3. claims: 1-7, 10-16 (each partial); 8 and 9 (complete)

compounds (and subject-matter referring to these compounds)  
of formula (I) wherein RA is a heterocyclic bicyclic system  
and R5 is a heterocyclic bicyclic system wherein ring (a)  
is aromatic and ring (b) is non-aromatic.  
---

4. claims: 1-7, 10-16 (each partial)

compounds (and subject-matter referring to these compounds)  
of formula (I) wherein RA is a heterocyclic bicyclic system  
and R5 is a heterocyclic bicyclic system wherein ring (a) is  
non-aromatic and ring (b) is aromatic.  
---

5. claims: 1-7, 10-16 (each partial)

compounds (and subject-matter referring to these compounds)  
of formula (I) wherein RA is a heterocyclic bicyclic system  
and R5 is a heterocyclic bicyclic system wherein both  
rings (a) and (b) are aromatic.  
---



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06754

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0208224	A	31-01-2002	AU 8974901 A BR 0112750 A CA 2417192 A1 CN 1452619 T CZ 20030243 A3 WO 0208224 A1 EP 1305308 A1 NO 20030345 A	05-02-2002 09-09-2003 31-01-2002 29-10-2003 17-09-2003 31-01-2002 02-05-2003 10-03-2003
WO 02056882	A	25-07-2002	WO 02056882 A1 EP 1359908 A1	25-07-2002 12-11-2003
WO 03064421	A	07-08-2003	WO 03064421 A1	07-08-2003
WO 03064431	A	07-08-2003	WO 03064431 A2	07-08-2003
US 6323217	B2	25-10-2001	FR 2804429 A1 AU 1674701 A BR 0100234 A CA 2332513 A1 CN 1314345 A EA 3096 B1 EP 1122254 A2 HU 0100489 A2 JP 2001233874 A NO 20010522 A NZ 509636 A PL 345528 A1 US 2001034352 A1 ZA 200100864 A	03-08-2001 02-08-2001 28-08-2001 31-07-2001 26-09-2001 26-12-2002 08-08-2001 29-05-2002 28-08-2001 01-08-2001 28-09-2001 13-08-2001 25-10-2001 08-08-2001
EP 0445862	A	11-09-1991	AT 191912 T AU 636012 B2 AU 7207991 A BG 60381 B1 CA 2037575 A1 CN 1054598 A , B CN 1054778 A CS 9100460 A2 CY 2235 A DE 69132119 D1 DE 69132119 T2 DK 445862 T3 EP 0445862 A2 ES 2147175 T3 FI 911096 A GR 3033461 T3 HK 1010727 A1 HR 930483 A1 HU 60733 A2 HU 9500241 A3 IE 910710 A1 IL 97018 A JP 2601566 B2 JP 4211685 A KR 177521 B1 LT 846 A , B LV 10085 A , B	15-05-2000 08-04-1993 12-09-1991 31-01-1995 07-09-1991 18-09-1991 25-09-1991 15-10-1991 04-07-2003 25-05-2000 21-12-2000 04-09-2000 11-09-1991 01-09-2000 07-09-1991 29-09-2000 08-09-2000 31-12-1995 28-10-1992 28-08-1995 11-09-1991 27-11-1995 16-04-1997 03-08-1992 20-03-1999 27-02-1995 10-05-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06754

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0445862	A	NO 910863 A ,B,	09-09-1991
		NZ 237189 A	25-11-1992
		PL 289323 A1	09-03-1992
		PL 168384 B1	29-02-1996
		PL 168686 B1	29-03-1996
		PL 168693 B1	29-03-1996
		PL 168356 B1	29-02-1996
		PL 169238 B1	28-06-1996
		PT 96937 A ,B	31-10-1991
		SG 47482 A1	17-04-1998
		SI 9110396 A ,B	31-12-1997
		SK 282406 B6	07-01-2002
		SK 282407 B6	07-01-2002
		RU 2070884 C1	27-12-1996
		US 5185335 A	09-02-1993
		US 5262418 A	16-11-1993
		ZA 9101611 A	25-11-1992
		ZW 2391 A1	07-09-1992
GB 1375836	A	27-11-1974	
		BE 779578 A4	18-08-1972
		CA 973882 A1	02-09-1975
		CH 570996 A5	31-12-1975
		DE 2207258 A1	07-09-1972
		DK 134553 B	29-11-1976
		FR 2135126 A5	15-12-1972
		JP 55045553 B	18-11-1980
		NL 7201854 A	22-08-1972
		SE 383746 B	29-03-1976
US 5610157	A	11-03-1997	
		US 5552553 A	03-09-1996
		US 5374637 A	20-12-1994
		US 5616738 A	01-04-1997
		US 5521314 A	28-05-1996
		US 5576448 A	19-11-1996
		US 5554772 A	10-09-1996
		US 5565582 A	15-10-1996
		US 5616583 A	01-04-1997
		US 5536733 A	16-07-1996
		US 5602129 A	11-02-1997
		US 5739134 A	14-04-1998
		AT 128132 T	15-10-1995
		AU 616838 B2	07-11-1991
		AU 5209190 A	27-09-1990
		CA 2012432 A1	22-09-1990
		CN 1045781 A ,B	03-10-1990
		CY 1921 A	07-03-1997
		DE 69022453 D1	26-10-1995
		DK 389037 T3	16-10-1995
		EP 0389037 A1	26-09-1990
		ES 2081340 T3	01-03-1996
		FI 101624 B1	31-07-1998
		FI 944076 A	05-09-1994
		GR 3017992 T3	29-02-1996
		HK 131596 A	26-07-1996
		HU 58322 A2	28-02-1992
		HU 9500311 A3	28-09-1995
		IE 67184 B1	06-03-1996
		IL 93817 A	30-03-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06754

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5610157	A	IL 110397 A	26-05-1995
		JP 2289566 A	29-11-1990
		JP 2845341 B2	13-01-1999
		KR 163587 B1	01-12-1998
		NO 901306 A ,B,	24-09-1990
		NZ 232964 A	26-07-1991
		PT 93531 A ,B	07-11-1990
		RU 2108332 C1	10-04-1998
		RU 2037492 C1	19-06-1995
		ZA 9002188 A	27-11-1991
		ZM 1290 A1	31-07-1992
		ZW 3390 A1	23-10-1991